Skip to main content
eLife logoLink to eLife
. 2023 Apr 6;12:e83604. doi: 10.7554/eLife.83604

The effect of weight loss following 18 months of lifestyle intervention on brain age assessed with resting-state functional connectivity

Gidon Levakov 1,†,, Alon Kaplan 2,3,, Anat Yaskolka Meir 2, Ehud Rinott 2, Gal Tsaban 2, Hila Zelicha 2, Matthias Blüher 4, Uta Ceglarek 4, Michael Stumvoll 4, Ilan Shelef 5, Galia Avidan 6,, Iris Shai 2,4,7,
Editors: Muthuswamy Balasubramanyam8, Christian Büchel9
PMCID: PMC10174688  PMID: 37022140

Abstract

Background:

Obesity negatively impacts multiple bodily systems, including the central nervous system. Retrospective studies that estimated chronological age from neuroimaging have found accelerated brain aging in obesity, but it is unclear how this estimation would be affected by weight loss following a lifestyle intervention.

Methods:

In a sub-study of 102 participants of the Dietary Intervention Randomized Controlled Trial Polyphenols Unprocessed Study (DIRECT-PLUS) trial, we tested the effect of weight loss following 18 months of lifestyle intervention on predicted brain age based on magnetic resonance imaging (MRI)-assessed resting-state functional connectivity (RSFC). We further examined how dynamics in multiple health factors, including anthropometric measurements, blood biomarkers, and fat deposition, can account for changes in brain age.

Results:

To establish our method, we first demonstrated that our model could successfully predict chronological age from RSFC in three cohorts (n=291;358;102). We then found that among the DIRECT-PLUS participants, 1% of body weight loss resulted in an 8.9 months’ attenuation of brain age. Attenuation of brain age was significantly associated with improved liver biomarkers, decreased liver fat, and visceral and deep subcutaneous adipose tissues after 18 months of intervention. Finally, we showed that lower consumption of processed food, sweets and beverages were associated with attenuated brain age.

Conclusions:

Successful weight loss following lifestyle intervention might have a beneficial effect on the trajectory of brain aging.

Funding:

The German Research Foundation (DFG), German Research Foundation - project number 209933838 - SFB 1052; B11, Israel Ministry of Health grant 87472511 (to I Shai); Israel Ministry of Science and Technology grant 3-13604 (to I Shai); and the California Walnuts Commission 09933838 SFB 105 (to I Shai).

Research organism: Human

eLife digest

Obesity is linked with the brain aging faster than would normally be expected. Researchers are able to capture this process by calculating a person’s ‘brain age’ – how old their brain appears on detailed scans, regardless of chronological age. This approach also helps to monitor how certain factors, such as lifestyle, can influence brain aging over relatively short time scales. It is not clear whether lifestyle interventions that promote weight loss can help to slow obesity-driven brain aging.

To answer this question, Levakov et al. studied 102 individuals who met the criteria for obesity and took part in a lifestyle intervention aimed to improve diet and physical activity levels over 18 months. The participants received a brain scan at the beginning and the end of the program; additional tests and measurements were also conducted at these times to capture other biological processes impacted by obesity, such as liver health.

Levakov et al. used the brain scans taken at the start and end of the study to examine the impact of the lifestyle intervention on the aging trajectory. The results revealed that a reduction in body weight of 1% led to the participants’ brain age being nearly 9 months younger than the expected brain age after 18 months. This attenuated aging was associated with changes in other biological measures, such as decreased liver fat and liver enzymes. Increases in liver fat and production of specific liver enzymes were previously shown to negatively impact brain health in Alzheimer’s disease. Finally, examining more closely the food consumption reports completed by participants showed that reduced consumption of processed food, sweets and beverages were linked to attenuated brain aging.

The findings show that lifestyle interventions which promote weight loss can have a beneficial impact on the aging trajectory of the brain observed with obesity. The next steps will include determining whether slowing down obesity-driven brain aging results in better clinical outcomes for patients. In addition, the work by Levakov et al. demonstrates a potential strategy to evaluate the success of lifestyle changes on brain health. With global rates of obesity rising, identifying interventions that have a positive impact on brain health could have important clinical, educational and social impacts.

Introduction

Brain aging is a complex, multifaceted process with various manifestations in different periods of the human lifespan, brain regions, and imaging modalities (Jack et al., 2017; Bethlehem et al., 2022). Nevertheless, reducing this complex process to a single scalar, the predicted brain age, may capture multiple conditions and risk factors associated with deviation from the normal aging trajectory (Cole and Franke, 2017). Brain age estimation is typically done by predicting chronological age from neuroimaging data in a healthy training group of subjects and applying the fitted model to a new, unseen individual. This procedure enables estimating a measure of brain age independent of the individual’s chronological age. Over-estimation of brain age, in relation to chronological age, is observed in several neurological conditions such as mild cognitive impairment, Alzheimer’s disease (AD), schizophrenia, and depression (Liem et al., 2017; Koutsouleris et al., 2014; Bashyam et al., 2020), and is associated with an increase in mortality rate (Cole et al., 2018). Similarly, over-estimation of brain age was also found in obesity (Franke et al., 2014; Kolenic et al., 2018; Ronan et al., 2016), suggesting that the brain age framework may provide a powerful tool for assessing accelerated brain aging due to excessive weight. Critically, it is unclear whether dietary lifestyle interventions may have a beneficial, attenuative effect on the brain aging process.

Obesity is associated with multiple adverse health impacts also observed in normal aging (Salvestrini et al., 2019; Tam et al., 2020). These comorbidities of obesity and typical aging include the risk of cardiovascular disease (Park et al., 2013), inflammation (Frasca et al., 2017), type 2 diabetes (Ahima, 2009), DNA damage (Niedernhofer et al., 2018; Shimizu et al., 2014), and neurodegenerative processes (Pugazhenthi et al., 2017). The link between excessive weight and neuronal damage is likely mediated by adiposity, metabolic dysfunction, and alteration in the gut microbiome (Gupta et al., 2020; Farruggia and Small, 2019). These, in turn, promote inflammatory metabolic processes in the central nervous system (Leigh and Morris, 2020). Accordingly, reduction in gray and white matter volume (Kullmann et al., 2015; García-García et al., 2019), changes in brain connectivity (Parsons et al., 2022; Daoust et al., 2021), cognitive impairment (Yang et al., 2018), and the prevalence of dementia (Pedditzi et al., 2016) were all associated with midlife obesity. These anatomical (Bethlehem et al., 2022), functional (Sala-Llonch et al., 2015), and behavioral (Fjell et al., 2017) findings are also observed during normal aging. An increase in life expectancy (Chang et al., 2019) along with a sharp growth in obesity rates (Abarca-Gómez et al., 2017) elicit the need to characterize, treat, and perhaps prevent obesity-related brain aging.

We previously found that weight loss, glycemic control, lowering of blood pressure, and increment in polyphenols-rich food were associated with an attenuation in brain atrophy (Kaplan et al., 2022). Obesity is also manifested in aging-related changes in the brain’s functional organization as assessed with resting-state functional connectivity (RSFC). These changes are dynamic (Honey et al., 2007) and can be observed in short time scales (Bassett et al., 2011) and thus of relevance when studying lifestyle intervention. Studies have linked obesity with decreased connectivity within the default mode network (Doucet et al., 2018; Beyer et al., 2017) and increased connectivity with the lateral orbitofrontal cortex (Parsons et al., 2022), which are also seen in normal aging (Sala-Llonch et al., 2015; Lopez et al., 2020). Longitudinal trials have reported changes in these connectivity patterns following weight reduction (McFadden et al., 2013; Lowe et al., 2019), indicating that they can be altered. However, findings regarding functional changes are less consistent than those related to anatomical changes due to the multiple measures (Rubinov and Sporns, 2010) and scales Mišić and Sporns, 2016 used to quantify RSFC. Hence, focusing on a single measure, the functional brain age may better capture these complex changes and their relation to aging.

Here, as a sub-study of the Dietary Intervention Randomized Controlled Trial Polyphenols Unprocessed Study (DIRECT-PLUS Yaskolka Meir et al., 2021b), we examined the effect of successful weight loss following 18 months of lifestyle intervention on brain aging attenuation (Figure 1). We assessed brain age based on RSFC taken before and after the intervention. Brain aging attenuation was quantified as the difference between the expected and observed brain age after the intervention. We trained and validated the age prediction model using two separate cohorts (n=291 [Nooner et al., 2012], 358 [Shafto et al., 2014; Taylor et al., 2017]), then applied it to our group of participants from the DIRECT-PLUS (n=102). We hypothesized that a successful reduction in anthropometric measurements following the intervention would attenuate brain aging. We then examined how multiple clinical outcomes, including liver, glycemic, lipids, and magnetic resonance imaging (MRI) fat deposition markers, would be related to attenuated brain aging. Finally, we report the correlation between brain age attenuation and changes in reported food consumption. To the best of our knowledge, this is one of the first studies that examined the beneficial effect of successful weight loss on the brain aging trajectory in humans, assessed by resting-state fMRI.

Figure 1. Study design and workflow.

Figure 1.

The Dietary Intervention Randomized Controlled Trial Polyphenols Unprocessed Study (DIRECT-PLUS) trial examined the effect of successful weight loss following 18-month lifestyle intervention on adiposity, cardiometabolic, and brain health across intervention groups. (a) Participants in the functional connectivity sub-study (N=132) completed the baseline measurements at T0. They were randomly assigned to three intervention groups: healthy dietary guidelines (HDG), an active control group, Mediterranean diet (MED), and green-MED. All groups were combined with physical activity (PA). Eighteen months following intervention onset, all measurements were retaken (T18). (b) Measurements included anthropometric measurements, blood biomarkers, fat deposition, and structural and functional brain imaging. (c) Functional brain imaging was conducted while subjects were at rest and was used to estimate resting-state functional connectivity (RSFC). RSFC measures the correlation between the time series of pairs of brain regions. (d) We fitted a linear support vector regression to predict chronological age from all pairwise correlations. We fitted the model on the Nathan Kline Institute (NKI) dataset, then tested and applied it to the Cambridge Centre for Ageing and Neuroscience (Cam-CAN) and the DIRECT-PLUS data. (e, left scatter plot) Based on the T0 data, we first computed the expected aging trajectory as the linear relation between the chronological and predicted age of all subjects. The fitted line represents the increase in the predicted age in relation to chronological age in the absence of an intervention. (e, right scatter plot) The fitted line was used to estimate the expected brain age at T18, given each participant’s T0 brain age and the time passed between the T0 and T18 magnetic resonance imaging (MRI) scans. We computed the observed brain age by applying the brain age model to the T18 scans. Brain age attenuation was calculated as the expected brain age minus the observed at T18.

Methods

In line with (Simmons et al., 2012) 21-word solution, we report how we determined our sample size, all data exclusions, all manipulations, and all measures in the study.

Dataset used for training and validating the brain age model

Training, validation, and testing of the brain age model were conducted on data from two cohorts that included functional and structural brain MRI. The training was conducted on the enhanced Nathan Kline Institute (NKI)-Rockland Sample (Nooner et al., 2012) and testing on the Cam-CAN dataset (Shafto et al., 2014; Taylor et al., 2017). The NKI dataset is composed of 291 subjects (226 females, 65 males) recruited from Rockland County, USA. All participants provided informed consent and the study was approved by the Institutional Review Board at the Nathan Kline Institute (#226781 and #239708) and Montclair State University (#000983A and #000983B). The Cam-CAN dataset includes 358 (193 females, 165 males) subjects roughly uniformly distributed from Cambridge City, UK. All participants provided informed consent, and the study was approved by the local ethics committee, Cambridgeshire 2 Research Ethics Committee (reference: 10/H0308/50). In both datasets, we included only subjects within the DIRECT-PLUS age range (34–82 years). Exclusion criteria included unsuccessful completion of the preprocessing and quality control stages (see MRI preprocessing).

Study design

This work was based on a sub-study of the DIREC-PLUS trial (clinicaltrials.gov ID: NCT03020186). The primary aims of the DIRECT-PLUS trial were 18-month changes in VAT, intrahepatic fat, and adiposity across intervention groups. The results for the primary outcomes were presented in separate publications (Yaskolka Meir et al., 2021b). The DIRECT-PLUS was launched in May 2017 and conducted in an isolated workplace in Israel (Nuclear Research Center Negev, Dimona, Israel). Most clinical and medical measurements, including anthropometric measurements, blood drawing, and lifestyle intervention sessions, were performed on-site. Among 378 volunteers, 294 met age (30+ years of age) and abdominal obesity inclusion criteria waist circumference (WC): men >102 cm, women >88 cm (U.S. Department of Health and Human Services, 2013; Centers for Disease Control and Prevention, 2020) or dyslipidemia (TG >150 mg/dL and high-density-lipoprotein-cholesterol [HDL-C] ≤40 mg/dL for men, ≤50 mg/dL for women [Grundy et al., 2005]). Exclusion criteria were inability to perform physical activity (PA); serum creatinine ≥2 mg/dL; serum alanine aminotransferase or aspartate aminotransferase more than three times above the upper limit of normal; a major illness that might require hospitalization; pregnancy or lactation; active cancer, or chemotherapy treatment in the last 3 years; warfarin treatment; pacemaker or platinum implantation; and participation in a different trial. Among 294 eligible participants, 132 participants were randomly assigned to participate in the fMRI sub-study. The Soroka Medical Center Medical Ethics Board and Institutional Review Board provided ethics approval. All participants provided written consent and received no financial compensation.

Randomization and intervention

All participants completed the baseline measurements and were randomized, using a computer-based program, in a 1:1:1 ratio, stratified by sex and work status (to ensure equal workplace-related lifestyle features between groups), into one of the three intervention groups: healthy dietary guidelines (HDG) as an active control group, Mediterranean diet (MED), green-MED, all combined with PA. Interventions lasted for 18 months and were contemporaneous, and participants were not blind to group assignment (open-label protocol). Each participant received complete dietary guidance (based on the specific intervention group) and a free and fully available clinical dietitians consult. Furthermore, all participants received free gym membership, including educational sessions encouraging moderate-intensity PA. Participants in both MED groups were assigned to a diet rich in vegetables, with poultry and fish replacing beef and lamb, with 1500–1800 kcal/day for men, 1200–1400 kcal/day for women. The diet additionally included 28 g/day of walnuts (+440 mg/day polyphenols provided). The green-MED group further consumed green tea (3–4 cups/day) and Wolffia globosa green shake (100 g/day frozen cubes, +1240 mg/day total polyphenols provided). A detailed description of the intervention outline is available in Supplementary file 1.

MRI acquisition

MRI scans were conducted at the Soroka University Medical Center (SUMC), Beer Sheva. Participants were scanned in a 3T Philips Ingenia scanner (Amsterdam, The Netherlands) equipped with a standard head coil. Subjects were instructed to refrain from food and non-water beverages 2 hr before the MRI sessions. Each of the two sessions at T0 and T18 included 2 RS-fMRI runs of 7 min each and a 3D T1-weighted anatomical scan to allow registration of the functional data. Before each RS session, participants were instructed to remain awake with their eyes open and lie still. fMRI BOLD contrast was acquired using the gradient-echo echo-planner imaging sequence with parallel acquisition (SENSE: factor 2.2). Scanning parameters were as follows: whole-brain coverage 41 slices (3 × 3 × 3 mm3), transverse orientation, 3 mm thickness, no gap, TR = 2200 ms, TE = 30 ms, flip angle = 90°, FOV = 200 × 222 (RL × AP) and matrix size 68 × 71 (RL × AP). High-resolution anatomical volumes were acquired with a T1-weighted 3D pulse sequence (1 × 1 × 1 mm3, 150 slices).

MRI preprocessing

The preprocessing pipelines used in this work were extensively described in a previous publication (Levakov et al., 2021). T1w scans were preprocessed through FreeSurfer’s (Fischl et al., 1999) (version 6.0) recon-all processing. FreeSurfer’s cortical segmentation and spherical warp were used to transfer the Schaefer 100-node cortical parcellation (Schaefer et al., 2018) to each subject’s volumetric anatomical space. Functional images of the NKI dataset were preprocessed with fMRIPrep (version 1.1.8; Esteban et al., 2019) and images of the DIRECT-PLUS and Cam-CAN datasets were preprocessed with the Configurable Pipeline for the Analysis of Connectomes (C-PAC [Cameron et al., 2013] version 1.6.2). Briefly, both pipelines included the following steps: slice-timing correction, motion correction, skull stripping, estimation of motion parameters, and other nuisance signal time series. For the NKI dataset, functional scans were bandpass filtered (0.008–0.08 Hz) and confound regressed in a manner orthogonal to the temporal filters. Confounds included six motion estimates, the mean time series derived in CSF, WM, and whole-brain masks, the derivatives of these nine regressors, and the squares of these 18 terms. Spike regressors were added for each frame with framewise displacement above 0.5 mm. Data were linearly detrended and standardized. Nuisance regression in the DIRECT-PLUS and Cam-CAN fMRI dataset included the first five principal components of the signal from white matter and CSF (Behzadi et al., 2007), six motion parameters, and linear and quadratic trends, global signal regression, followed by temporal filtering between 0.1 and 0.01 Hz. Finally, a scrubbing threshold of 0.5 mm frame-wise displacement was applied (Power et al., 2014) (removal of 1 TR before and 2 TR after excessive movement). The time series of the two functional scans in the DIRECT-PLUS were concatenated to a single T0 and T18 scans. The exclusion criterion for excessive movements was determined a priori to less than 70% (9 min and 48 s) of the resting-state session after the scrubbing procedure (23% omitted; 102 subjects left). In all datasets, functional connectivity was defined as the Pearson’s correlation among pairs of ROIs’ time series followed by Fisher’s r-to-z transformation.

Clinical measurement and blood biomarkers

All parameters were measured at baseline and after 18 months of intervention. All clinical measures in the current study were selected a priori from a large pool of variables taken in the DIRECT-PLUS trial (Yaskolka Meir et al., 2021b). These measures were taken from five pre-selected categories: (1) Anthropometry that includes body mass index (BMI) and WC; (2) liver biomarkers that included AST, alanine transaminase (ALT), gamma-glutamyl transferase (GGT), ALKP, FGF 21, and chemerin; (3) glycemic markers, including glucose HOMA-IR and HbA1c; (4) lipids including cholesterol, HDL-C, LDL-C, and triglycerides; (5) imaging measures included liver fat, VAT, DSC, SSC, and the hippocampal occupancy score (HOC). WC was measured to the nearest millimeter halfway between the last rib and the iliac crest using an anthropometric measuring tape. Blood and urine samples were collected at 8:00 AM after a 12 hr fast. Blood samples were centrifuged and stored at –80°C. HOC was calculated as the hippocampal volume divided by (hippocampal volume + inferior lateral ventricle volume) in each hemisphere, then averaged across hemispheres (Kaplan et al., 2022; Heister et al., 2011).

Nutritional assessment

Assessment of nutritional intake and lifestyle habits was self-reported online using validated food frequency questionnaires (FFQ) (Shai et al., 2005). The questionnaires were administered at baseline, after 6 months, and at the end of the trial. We selected a priori the questionnaire variables that were associated with brain age attenuation. These variables included the change in the following categories: sweets and beverages, weekly Wolffia globose intake, nut and seeds, eggs and milk, beef, processed food, green tea, and walnuts. The closed workplace enabled monitoring of the freely provided lunch and the intense dietary and PA sessions, which were provided simultaneously to all three groups.

Liver and visceral fat imaging protocols

To quantify and follow IHF% changes, we used H-MRS, a reliable tool for liver fat quantification (Kukuk et al., 2015). Localized, single-voxel proton spectra were acquired using a 3.0 T magnetic resonance scanner (Philips Ingenia, Best, The Netherlands). The measurements were taken from the right frontal lobe of the liver, with a location determined individually for each subject using a surface, receive-only phased-array coil. Spectra with and without water suppression were acquired using the single-voxel stimulated echo acquisition mode with the following parameters: TR = 4000 ms, TE = 9.0 ms, and TM = 16.0 ms. The receiver bandwidth was 2000 Hz and the number of data points was 1024. Second-order shimming was used. Four averages were taken in a single breath hold for an acquisition time of 16 s. The total image hepatic fat fraction was determined as the ratio between the sum of the area under all fat divided by the sum of area under all fat and water peaks (Hu et al., 2010).

Abdominal fat depots were assessed at baseline and 18 months thereafter using 3 T MRI scans (Ingenia 3.0T, Philips Healthcare, Best, the Netherlands). The scanner utilized a 3D modified DIXON imaging technique without gaps (2 mm thickness and 2 mm of spacing), fast-low-angle shot sequence with a multi-echo two excitation pulse sequence for phase-sensitive encoding of fat and water signals (TR, 3.6 ms; TE1, 1.19 ms; TE2, 2.3 ms; FOV 520 × 440 × 80 mm3; 2 × 1.4 × 1 mm3 voxel size). Four images of phantoms were generated: in-phase, out-phase, fat, and water phase (Thomas et al., 2013). Participants were instructed to hold their breath to avoid motion artifacts when their abdomen was scanned. A continuous line over the fascia superficialis was drawn to differentiate deep-SAT from superficial-SAT and calculated mean VAT, deep-SAT, and superficial-SAT along two axial slices: L5-S1 and L4-L5. We quantified fat mass regions as area and relative proportion of each fat subtype (percentage).

Brain age estimation

Subjects’ chronological age was predicted from the lower triangle of the functional connectivity matrix depicting all unique edges (4950 edges). We used a support vector regression model (Smola et al., 2000) implemented using Scikit-learn (Fabian et al., 2011) with a linear kernel and all the default parameters. Model accuracy was quantified as the Pearson’s correlation between the observed and predicted age. We additionally report the mean absolute error (MAE) in years, along with a p-value based on a non-parametric permutation test created by shuffling the data labels 1000 times (Hilger et al., 2020).

Statistical analysis

The primary outcome of the current work was brain age attenuation quantified as the difference between the expected and observed brain age at T18 (Yaskolka Meir et al., 2021a). The expected brain age at T18 was calculated by first producing brain age prediction for all participants at T0. Then, a linear regression was used to estimate brain age from the chronological age at T0. The fitted regression formula, representing the expected aging trajectory in the absence of intervention, was used to estimate the expected brain age at T18 given each participant’s T0 brain age and the time passed between the T0 and T18 MRI scans. The observed brain age was produced by applying the brain age model to the T18 scans. At baseline, brain age gap was computed as the difference between the predicted and observed age after regressing out the effect of the chronological age on the this gap (brain age bias correction [Smith et al., 2019]). We note that the result of computing the difference between the bias corrected brain age gap at both times was nearly identical to the brain age attenuation measure (r=0.99, p<0.001; MAE = 0.45). The difference between the two is because the brain age attenuation model takes into account the difference in the exact time that passed between the two scans for each participant (mean = 21.36 m, std = 1.68 m). Association between brain age attenuation and change in clinical measures following the intervention were reported using Pearson’s correlation. Correction for multiple comparisons was conducted within each biomarker category using the Benjamini–Hochberg false discovery rate (FDR; Benjamini and Hochberg, 1995) with an alpha of 0.05. Associations to food consumption reports were reported using Kendall’s tau correlation for ordinal data. Processed food at T18 had only two levels, ‘same consumption’ and ‘less consumption’, thus relation to brain age attenuation was tested with independent t-test. Change in clinical measurements were computed as a delta (Δ), the value at T0 minus the value at T18. We quantified change in reported food consumption as the change between the T0 and T18 questionnaires for food groups (i.e. processed food, sweets, and beverages) and as total consumption for polyphenols-provided foods (i.e. Mankai, green tea, walnuts). To control for the possible effect of age or gender, we used partial regression by regressing out the linear effect of age and gender from both brain age attenuation and the clinical measures. This was done by predicting each clinical measure, with the covariate as a predictor, keeping only the residual.

Effect size in previous work

In a recent study (Zeighami et al., 2022), the authors reported a significant decrease in delta age 12 months following bariatric surgery. We converted the reported t statistic (t=3.66, p<0.001, df = 85) to an effect size (Cohen’s d=0.79, r=0.369) using an effect size calculator (https://lbecker.uccs.edu/). Using a sample size calculator (Python statsmodels.stats.power), we found that with an alpha of 0.05 and beta >0.05, a sample size >90 is required. With the given sample size (n=102), the probability of failing to reject the null hypothesis under the alternative hypothesis (β, Type II error rate) is 3%. Alternatively, for a Type II error rate lower than 0.1 with the given sample size, an effect size of 0.664 (Cohen’s d) is required.

Results

Brain age estimation

To estimate chronological age from RSFC, we utilized data from 649 participants from two separate cohorts for the brain age model training, validation, and testing. We predicted chronological age from functional connectivity among the 100 nodes of the Schaefer brain atlas (Schaefer et al., 2018) (4950 edges) using a linear support vector regression model. The model was first trained and validated on 291 participants from the NKI dataset (Nooner et al., 2012; n=291) using fivefold cross-validation. As expected, a positive correlation was found between the predicted and observed age (r=0.439, p<0.001; MAE = 8.544, p<0.001). Next, we retrained the model on the entire sample and tested it in an independent sample from the Cam-CAN dataset (Shafto et al., 2014; n=358) again, yielding a positive correlation between the predicted and observed age (r=0.290, p<0.001; MAE = 11.402, p=0.005). Finally, we used the fitted model to estimate the brain age within the DIRECT-PLUS cohort. Of the 132 subjects that participated in the fMRI sub-study, 102 were included in all analyses after exclusions due to excessive in-scanner motion (23% omitted; MRI preprocessing). The predicted brain age and observed chronological age were correlated (r=0.244, p=0.013; MAE = 8.337, p<0.001; Figure 2), reproducing the results found within the two other datasets. Despite being significant and reproducible, we note that the correlations between the observed and predicted age were relatively moderate.

Figure 2. Prediction accuracy within the validation and test cohorts.

The scatter plots depict the data points and regression line between the predicted (y-axis) and observed (x-axis) age. The predicted-observed correlation is presented for the validation data (left), the Cambridge Centre for Ageing and Neuroscience (Cam-CAN) test data (middle), and the Dietary Intervention Randomized Controlled Trial Polyphenols Unprocessed Study (DIRECT-PLUS) data at baseline. The shaded area around the regression lines represents a 95% confidence interval estimated using bootstrapping. Pearson’s correlation, MAE (mean absolute error), and corresponding p-values are shown at the bottom of each plot. The dotted lines represent a perfect correlation for reference (predicted = observed).

Figure 2.

Figure 2—figure supplement 1. Brain age prediction accuracy of individual nodes.

Figure 2—figure supplement 1.

We reiterated the model training procedure for each of the nodes separately. We extracted the row of each node in the resting-state functional connectivity (RSFC) matrix, which represents all the nodes’ connections with the rest of the brain, or its ‘connectivity fingerprint’. As in the original model, we used a linear support vector regression fitted on the Nathan Kline Institute (NKI) dataset, then tested it on the Cambridge Centre for Ageing and Neuroscience (Cam-CAN) dataset. Prediction accuracy was quantified as the correlation between chronological age and predicted age. (a) Prediction accuracy was depicted on the brain surface on a lateral (top) and medial (bottom) view. (b) Box plot showing the prediction accuracy (y-axis) in each of the seven canonical resting-state networks Zelicha et al., 2019. Each dot represents a single node.

Baseline characteristics

Baseline characteristics among the 102 participants with valid RSFC MRI scans are presented in Table 1 (see Supplementary file 2 for additional measures). The mean participant age was 51.5±10.5 years (median = 50.6, range 33.9–81.9), and 91.2% were men. The mean BMI and WC were 30.1±2.5 kg/m2 and 107.1±6.6 cm, respectively. The mean baseline predicted brain age by RSFC was 52.8±4 years. In Table 1 we report the correlation between baseline characteristics and age, predicted age, and the brain age gap. The brain age gap was computed as the difference between the predicted and observed age after regressing out the effect of age on the this gap (brain age bias correction [Smith et al., 2019]). At baseline, brain age gap was correlated with chemerin (r=0.22, p=0.029), and with obesity-associated measurements obtained by MRI including visceral abdominal tissue (VAT): r=0.23, p=0.02 and superficial subcutaneous fat (SSC): r=−0.25, p=0.014.

Table 1. Association between baseline characteristics and age, predicted age, and brain age gap.

Age Brain age T0 brain age gap(bias corrected)
r p-Value r p-Value r p-Value
BMI (kg/m²) –0.110 0.272 0.067 0.504 0.097 0.334
Chemerin (ng/mL) 0.153 0.124 0.247 0.012 0.216 0.029
HOMA IR 0.177 0.079 0.179 0.074 0.141 0.163
HbA1c (%) 0.315 0.001 0.117 0.240 0.042 0.677
HDL-C (mg/dL) 0.158 0.113 –0.095 0.343 –0.138 0.168
LDL-C (mg/dL) –0.152 0.129 –0.024 0.811 0.013 0.893
Triglycerides (mg/dL) –0.023 0.815 0.145 0.147 0.155 0.120
Liver fat (cm²) –0.039 0.711 0.156 0.132 0.170 0.101
VAT (cm²) 0.495 0.000 0.329 0.001 0.225 0.025

The relation between successful lifestyle intervention and attenuation of functional brain aging

Our primary hypothesis was that success in lifestyle intervention, as assessed by anthropometric measurements, will attenuate functional brain aging. Brain aging attenuation was quantified as the difference between the expected and observed brain age at T18 (Yaskolka Meir et al., 2021a; Figure 1e). Following 18 months of lifestyle intervention, participants showed a reduction of 0.76 (±1.86) units in BMI on average, 2.31 (±5.61) kg reduction in weight, and 5.39 (±5.89) cm reduction in WC. These constitute a –6.45% ± (5.60%) and –4.35% ± (5.86%) reduction from baseline for WC and BMI and weight, respectively. Additionally, at T18, the observed age was lower than expected in 56.8% of the subjects, while the opposite was found in 43.1% of the subjects (X2=1.922, p=0.166; see Figure 3, top). Importantly, we found a correlation between ∆BMI and brain age attenuation such that participants that showed a decrease in BMI also exhibited attenuated brain aging (r=0.319, p<0.001; Figure 3, bottom). Specifically, 1% of BMI or weight loss resulted in an 8.9 months’ attenuation of brain age (Figure 3—figure supplement 1). Similar results were found with ∆body weight (r=0.319, p<0.001) and ∆WC (r=0.198, p=0.046; Figure 4). The correlations to ∆BMI and ∆weight were significant after correcting for age and baseline brain age (p<0.05 for all), while the correlation to WC did not show a significant association (r>0.171, p’s <0.079 for all).

Figure 3. Observed compared to expected brain age at T18.

The upper panel depicts the chronological age (x-axis) and the observed (empty circles) and expected (full circles) brain age (y-axis) of each subject. The dashed line represents the expected brain age trajectory fitted based on the T0 data (see regression line in Figure 1e, left). Arrows point from the expected to the observed age of a single individual, corresponding to brain age attenuation. Arrows’ colors correspond to the extent of brain age attenuation (blue shades indicate attenuation, red shades indicate an acceleration in brain age). The observed age was lower than expected in 56.8% of the subjects, while the opposite was found in 43.1% (X2=1.922, p=0.166). In the lower panel, arrows were reordered by subjects’ body mass index (BMI) change over the 18 months of intervention. A significant correlation was found between the BMI and brain age change (r=0.319, p<0.001). This is evident in the graph, such that most of the blue arrows are located on the left side of the x-axis (negative values), and most of the red arrows appear on the right side (positive values).

Figure 3—source data 1. Participants’ demographics predicted and observed age and weight values.
A processed version of the data that includes participants’ demographics, predicted, and observed age and weight values for T0 and T18.

Figure 3.

Figure 3—figure supplement 1. Brain age attenuation compared to percent weight reduction from baseline.

Figure 3—figure supplement 1.

A scatter plot depicting the linear relationship between percent weight reduction from baseline (x-axis) and years of brain age attenuation (y-axis). Also shown on the graph are the correlation coefficient and the parameters of the linear relation between the two variables. One percent of body weight loss corresponded to an 8.9 months’ attenuation of brain age. The shaded area around the regression line represent a 95% confidence interval estimated using bootstrap.

Figure 4. Brain age attenuation association with clinical measurements.

Figure 4.

The scatter plots depict the data points and regression line between brain age attenuation (y-axis) and each clinical measurement (x-axis). Clinical measurements include anthropometry (blue), liver markers (orange), glycemic markers (brown), lipid profile (red), and fat deposition measured using magnetic resonance imaging (MRI) (green). The shaded area around the regression line represents a 95% confidence interval estimated using bootstrapping. Pearson’s correlation and the corresponding p-value are shown at the bottom of each plot. Significant associations following false discovery rate (FDR) correction are marked in bold (*=p < 0.05, **=p < 0.01).

The relation between brain age attenuation and clinical measurements

To examine the clinical outcomes associated with attenuated brain aging, we further tested the correlation of brain age attenuation with liver, glycemic, lipids, and MRI-assessed fat deposition biomarkers (Figure 4). Except of deep subcutaneous changes, all fat deposition measurements, superficial subcutaneous, visceral, and liver fat changes (e.g. loss) were significantly and directly associated with brain age attenuation (p<0.05, FDR corrected), i.e., the more the individual succeeded in diet-induced fat depots loss, the more brain age attenuation has been achieved. We then tested the association between brain age attenuation and liver and glycemic biomarkers. Out of all examined liver biomarkers, a decrease in ALT, GGT, alkaline phosphatase, and serum chemerin were significantly associated with attenuation in brain age (p<0.05 for all, FDR corrected). Of all examined lipid profile markers, only an increase in ∆HDL-C was significantly correlated with brain age attenuation (r=-0.273, p=0.005). Finally, a decrease in HOC was significantly correlated with brain age attenuation (r=-0.296, p=0.003). All results were reproduced after controlling for baseline age and predicted age at T0. However, after further correction for changes in BMI, only ∆alkaline phosphatase, ∆chemerin, and ∆HOC were associated with brain age attenuation (all p’s<0.018), with no significant associations with all other biomarkers (p>0.05, for all; see Supplementary file 3).

The relation between brain age attenuation and food consumption

We examined whether food consumption, as reported using an FFQ, could be associated with functional brain aging attenuation. Associations were tested using Kendall’s rank correlation. We began with categories that could negatively affect brain aging attenuation. In line with our hypothesis, we found that decreased consumption of processed food (t=3.131, p=0.002) and sweets and beverages (τ=−0.231, p=0.002) was associated with more attenuation in brain age. An increase in green tea and walnut consumption, for which we hypothesized an attenuation effect on brain aging due to their high polyphenol content, did not result in a significant correlation (all τ’s<0.081, p’s>0.121; see Supplementary file 4 for all measures).

Discussion

Considerable evidence implies that excessive weight accelerates normal aging (Salvestrini et al., 2019; Tam et al., 2020), a process that is also manifested in brain aging (Beck et al., 2022). In the current study, we examined for the first time whether weight loss following a lifestyle dietary intervention may attenuate the effect of obesity on the brain aging trajectory. We hypothesized that reducing anthropometric measurements following a lifestyle intervention would be associated with attenuated brain aging. We first demonstrated, across two separate cohorts, that age could be estimated from RSFC, as done in previous work (Dosenbach et al., 2010). We then applied the fitted age prediction model to the participants of the DIRECT-PLUS. We found that 1% of body weight loss results in an 8.9 months’ attenuation of brain age. Attenuated brain aging was further correlated with a decrease in WC, MRI-assessed fat deposition, liver biomarkers, and HDL-C. Finally, reduced reported consumption of processed food, sweets and beverages were also related to attenuated brain aging. During the 18-month trial, a modest average weight loss of 2.31 (±5.61) kg was observed. As demonstrated by our previous trials, as well as others, the maximum weight loss following lifestyle intervention is achieved in 6 months, following a regain/rebound phase. In addition, our trials and others have demonstrated an improvement in cardiometabolic health following a MED intervention (i.e. hepatic and visceral fat reduction and improved lipid profile), despite a modest weight loss (Yaskolka Meir et al., 2021b; Zelicha et al., 2022; Gepner et al., 2018; Estruch et al., 2013).

Accumulated evidence points to the potential of lifestyle intervention to reverse the negative impact of excess weight on brain structure, function, and cognition. Cross-sectional and longitudinal studies found that reported adherence to a MED was linked to increased gray matter volume in multiple regions (Staubo et al., 2017), including the hippocampus (Ballarini et al., 2021). Adherence to HDG was also associated with reduced cognitive decline (Gardener and Rainey-Smith, 2018). Importantly, randomized clinical trials can support a causal relationship between lifestyle intervention and the brain aging process. Such studies from our group (Kaplan et al., 2022) and others (Erickson et al., 2011; Espeland et al., 2016) revealed that subjects enrolled in a PA+dietary intervention exhibit lower hippocampal atrophy and smaller ventricles. A similar beneficial effect on cognitive functioning in middle age was also found (Valls-Pedret et al., 2015), along with functional connectivity alteration in the default mode and executive control networks (Voss et al., 2010; García-Casares et al., 2017). To date, a single study in rats has tested the effect of a dietary intervention using the brain age framework and found a reduction in brain aging rate (Brusini et al., 2022). Hence, the current work provides the first evidence that such a beneficial effect on brain age can also be found in humans.

Studying changes in functional brain aging is part of a broader field that examines changes in various biological ages, such as telomere length (Gampawar et al., 2020), DNA methylation (Fraga, 2009), and arterial stiffness (Hamczyk et al., 2020). Evaluating changes in these bodily systems over time allows us to capture health and lifestyle-related factors that affect overall aging and may guide the development of targeted interventions to reduce aging-related decline. For example, in the CENTRAL cohort, we recently reported that reducing body weight and intrahepatic fat following a lifestyle intervention was related to methylation age attenuation (Yaskolka Meir et al., 2021a). In the current work, we used RSFC for brain age estimation, which resulted in an MAE of ~8 years, that was larger than the intervention period. Nevertheless, we found that brain age attenuation was associated with changes in multiple health factors. The precision of an age prediction model based on RSFC is typically lower than a model based on structural brain imaging (de Lange et al., 2022). However, a higher model precision may result in a lower sensitivity to detect clinical effects (Bashyam et al., 2020; Jirsaraie et al., 2023). Better tools for data harmonization among datasets (Jirsaraie et al., 2023) and larger training sample size (de Lange et al., 2022) may improve the accuracy of such models in the future. We also suggest that examining the dynamics of multiple bodily ages and their interactions would enhance our understanding of the complex aging process (Yu et al., 2022; Franke and Gaser, 2019).

The brain age framework reduces the multifaceted aging process captured in a given imaging modality to a single scalar. This scalar, the predicted brain age, is well defined in the sense that it minimizes the prediction error within the training dataset. Moreover, the clinical relevance of functional brain age is shown, for example, in predicting Alzheimer’s onset (Gonneaud et al., 2021) and symptoms severity in depression (Dunlop et al., 2021). This reductionist approach raises several challenges. The first is the ability to interpret the features used by the machine learning model (Levakov et al., 2020). A second challenge is understanding the physiological factors that may affect its predictions (Mora, 2013), which we address in the current work. Here, we report how a set of clinical measures are associated with changes in brain aging. Importantly, lifestyle and other interventions can affect these measures to attenuate the brain aging process. We suggest that such mapping of changes in clinical outcomes to months or years of attenuated brain aging has important scientific, clinical, and even educational value.

We found that clinical outcomes that include anthropometric, liver, and lipid biomarkers were associated with attenuated brain age. Specifically, two main factors were linked to changes in brain age, changes in anthropometry measures, and liver status. The first factor included BMI, weight, WC, and superficial subcutaneous and visceral fat. The second factor included liver fat, ALT, GGT, alkaline phosphatase, and serum chemerin. Alkaline phosphatase and chemerin were also associated with changes in brain age after controlling for changes in BMI. The negative impact of elevated liver enzymes and liver fat on brain health is seen, for example, in the case of AD (Nho et al., 2019; Labenz et al., 2021; Ghareeb et al., 2011). This link is thought to be mediated by oxidative stress, vascular damage, and inflammation (Helfer and Wu, 2018). Chemerin, produced in the liver, is an adipokine linked to energy homeostasis, adipogenesis, and excessive weight (Helfer and Wu, 2018). Chemerin is correlated with age (Aronis et al., 2014) and BMI (Ernst and Sinal, 2010) and was found to be reduced following lifestyle intervention (Blüher et al., 2012; Ashtary-Larky et al., 2021). The relation between serum chemerin and brain aging is still unclear, but possible linking mechanisms are hypertension (Ferland et al., 2020) and inflammation (Ernst and Sinal, 2010). Besides these two factors, HDL-C was the only variable whose increase was correlated to brain aging attenuation. This is in line with evidence of the protective role of HDL-C in cognitive decline and dementia (Hottman et al., 2014). Finally, of all the reported food consumption items, only reduced consumption of processed food, sweets and beverages were linked to attenuated brain aging. Although these results are based on self-reports, they may be helpful for developing neuroprotective dietary guidelines (Smith et al., 2010).

It is important to consider several limitations and strengths of the current study. The first limitation was gender imbalance (F: 93, M: 9; F: 8.8%, M: 91.2%), which reflected the workplace profile from which participants were recruited (Yaskolka Meir et al., 2019; Tsaban et al., 2021; Rinott et al., 2021; Zelicha et al., 2019). This distribution misrepresents the proportion of obese women within the general population (F: 51%, M: 49%; Craig et al., 2020). Hence, these results should be further corroborated in a gender-balanced sample. Additionally, participants were recruited based on excess adiposity or dyslipidemia, therefore, they represented a restricted range of the normal population. This design allows to maximize the intervention effects but restricts our ability to detect correlation at baseline. We also note that the lack of a no-intervention control group limits our ability to directly relate our findings to the intervention. Hence, we can only relate brain age attenuation to the observed changes in health biomarkers. The strengths of the study lies in the wealth of health biomarkers that included anthropometric, blood, and imaging measures, the relatively large sample for similar intervention trials, the tight on-site monitoring over the dietary compliance, and the long intervention duration. Finally, the use of three distinct datasets for training and validation, testing, and inference supports the generalization of our model.

To conclude, in the current work, we examined how changes in multiple health factors, including anthropometric measurements, blood biomarkers, and fat deposition, can account for brain aging attenuation. We reveal that the two factors with the strongest association with brain aging were changes in anthropometry measures and liver biomarkers. These findings complement the growing interest in bodily aging indicated, for example, by DNA methylation (Yaskolka Meir et al., 2021a) as health biomarkers and interventions that may affect them. These exciting results may advance our knowledge of factors related to healthy brain aging and guide future neuroprotective interventions.

Acknowledgements

This work was supported by grants from: the German Research Foundation (DFG), German Research Foundation - project number 209933838 - SFB 1052; B11, Israel Ministry of Health grant 87472511 (to I Shai); Israel Ministry of Science and Technology grant 3-13604 (to I Shai); and the California Walnuts Commission (to I Shai).

Funding Statement

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Contributor Information

Gidon Levakov, Email: gidonle@post.bgu.ac.il.

Muthuswamy Balasubramanyam, Madras Diabetes Research Foundation, India.

Christian Büchel, University Medical Center Hamburg-Eppendorf, Germany.

Funding Information

This paper was supported by the following grants:

  • The German Research Foundation 209933838 SFB 1052 to Iris Shai.

  • Israel Ministry of Health grant 87472511 to Iris Shai.

  • Israel Ministry of Science and Technology 3-13604 to Iris Shai.

  • California Walnut Commission 09933838 SFB 105 to Iris Shai.

  • The German Research Foundation B11 to Iris Shai.

Additional information

Competing interests

No competing interests declared.

No competing interests declared.

has received consulting fees from Amgen, Astra Zeneca, Boehringer-Ingelheim, Bayer, Lilly, Novo Nordisk, Novartis, Sanofi and Pfizer; and fees for lectures/ presentations from Amgen, Astra Zeneca, Boehringer-Ingelheim, Bayer, Daiichi-Sankyo, Lilly, Novo Nordisk, Novartis, Sanofi and Pfizer. The author is also on the advisory board for Boehringer-Ingelheim. The author has no other competing interests to declare.

Author contributions

Conceptualization, Software, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing.

Data curation, Formal analysis, Validation, Investigation, Methodology, Writing – original draft, Project administration, Writing – review and editing.

Resources, Data curation, Project administration, Writing – review and editing.

Resources, Data curation, Project administration.

Resources, Data curation, Project administration.

Resources, Data curation, Project administration.

Resources, Project administration.

Resources, Project administration.

Resources, Project administration.

Resources, Methodology, Writing – review and editing.

Supervision, Investigation, Methodology, Project administration, Writing – review and editing.

Conceptualization, Resources, Data curation, Supervision, Funding acquisition, Validation, Investigation, Project administration, Writing – review and editing.

Ethics

Clinical trial registration clinicaltrials.gov ID: NCT03020186.

This work was based on a sub-study of the DIREC-PLUS trial (clinicaltrials.gov ID: NCT03020186). The Soroka Medical Center Medical Ethics Board and Institutional Review Board provided ethics approval. All participants provided written consent and received no financial compensation.

Additional files

Supplementary file 1. Intervention outline by group.

A table describing the details of the intervention for each of the three groups.

elife-83604-supp1.xlsx (10.2KB, xlsx)
Supplementary file 2. Association between baseline characteristics and age, predicted age, and brain age gap.

A table describing the Pearson’s correlation between baseline characteristics and age, predicted age, and brain age gap.

elife-83604-supp2.xlsx (11KB, xlsx)
Supplementary file 3. Correlation and partial correlation of brain age attenuation and the measured biomarkers.

A table describing the Pearson’s correlation and partial correlation of brain age attenuation and the change in the measured biomarkers.

elife-83604-supp3.xlsx (10.7KB, xlsx)
Supplementary file 4. Relation between brain age attenuation and food consumption.

A table describing the Kendall’s tau correlation coefficient of brain age attenuation and food consumption, as reported using a food frequency questionnaire (FFQ).

elife-83604-supp4.xlsx (9.5KB, xlsx)
MDAR checklist

Data availability

The code for the brain age prediction model and the calculation of brain age attenuation is openly available online at https://github.com/GidLev/functional_brain_aging (copy archived at Levakov et al., 2023). The unprocessed data used for the model training and validation is openly available online at http://fcon_1000.projects.nitrc.org/indi/enhanced/neurodata.html for the eNKI dataset and available upon online access request https://camcan-archive.mrc-cbu.cam.ac.uk/dataaccess/ for the CamCAN dataset. Data from the DIRECT-PLUS trial is not publicly available since it contains information that could compromise the privacy of research participants. However, de-identified data could be shared upon request, subject to approval from the Soroka Medical Center Medical Ethics Board. A processed version of the data that includes participants' demographics, predicted and observed age and weight values for T0 and T18 is available as Figure 3—source data 1.

The following previously published datasets were used:

Taylor JR, Williams N, Cusack R, Auer T, Shafto MA, Dixond M, Dixond LK, Tylerd LK, Cam Can, Richard NH. 2017. Magnetoencephalography (MEG) The Cambridge Centre for Ageing and Neuroscience.

Nooner KB, Colcombe SJ, Tobe RH, Mennes M, Benedict MM, Moreno AL, Panek LJ, Brown S, Zavitz ST, Li Q, Sikka S. 2012. NKI-RS Enhanced Sample. International Neuroimaging Data-sharing Initiative. SCR_010461

References

  1. Abarca-Gómez L, Abdeen ZA, Hamid ZA, Abu-Rmeileh NM, Acosta-Cazares B, Acuin C, Adams RJ, Aekplakorn W, Afsana K, Aguilar-Salinas CA, Agyemang C, Ahmadvand A, Ahrens W, Ajlouni K, Akhtaeva N, Al-Hazzaa HM, Al-Othman AR, Al-Raddadi R, Al Buhairan F, Al Dhukair S, Ali MM, Ali O, Alkerwi A, Alvarez-Pedrerol M, Aly E, Amarapurkar DN, Amouyel P, Amuzu A, Andersen LB, Anderssen SA, Andrade DS, Ängquist LH, Anjana RM, Aounallah-Skhiri H, Araújo J, Ariansen I, Aris T, Arlappa N, Arveiler D, Aryal KK, Aspelund T, Assah FK, Assunção MCF, Aung MS, Avdicová M, Azevedo A, Azizi F, Babu BV, Bahijri S, Baker JL, Balakrishna N, Bamoshmoosh M, Banach M, Bandosz P, Banegas JR, Barbagallo CM, Barceló A, Barkat A, Barros AJ, Barros MV, Bata I, Batieha AM, Batista RL, Batyrbek A, Baur LA, Beaglehole R, Romdhane HB, Benedics J, Benet M, Bennett JE, Bernabe-Ortiz A, Bernotiene G, Bettiol H, Bhagyalaxmi A, Bharadwaj S, Bhargava SK, Bhatti Z, Bhutta ZA, Bi H, Bi Y, Biehl A, Bikbov M, Bista B, Bjelica DJ, Bjerregaard P, Bjertness E, Bjertness MB, Björkelund C, Blokstra A, Bo S, Bobak M, Boddy LM, Boehm BO, Boeing H, Boggia JG, Boissonnet CP, Bonaccio M, Bongard V, Bovet P, Braeckevelt L, Braeckman L, Bragt MC, Brajkovich I, Branca F, Breckenkamp J, Breda J, Brenner H, Brewster LM, Brian GR, Brinduse L, Bruno G, Bueno-de-Mesquita HB, Bugge A, Buoncristiano M, Burazeri G, Burns C, de León AC, Cacciottolo J, Cai H, Cama T, Cameron C, Camolas J, Can G, Cândido APC, Capanzana M, Capuano V, Cardoso VC, Carlsson AC, Carvalho MJ, Casanueva FF, Casas JP, Caserta CA, Chamukuttan S, Chan AW, Chan Q, Chaturvedi HK, Chaturvedi N, Chen CJ, Chen F, Chen H, Chen S, Chen Z, Cheng CY, Chetrit A, Chikova-Iscener E, Chiolero A, Chiou ST, Chirita-Emandi A, Chirlaque MD, Cho B, Cho Y, Christensen K, Christofaro DG, Chudek J, Cifkova R, Cinteza E, Claessens F, Clays E, Concin H, Confortin SC, Cooper C, Cooper R, Coppinger TC, Costanzo S, Cottel D, Cowell C, Craig CL, Crujeiras AB, Cucu A, D’Arrigo G, d’Orsi E, Dallongeville J, Damasceno A, Damsgaard CT, Danaei G, Dankner R, Dantoft TM, Dastgiri S, Dauchet L, Davletov K, De Backer G, De Bacquer D, De Curtis A, de Gaetano G, De Henauw S, de Oliveira PD, De Ridder K, De Smedt D, Deepa M, Deev AD, Dehghan A, Delisle H, Delpeuch F, Deschamps V, Dhana K, Di Castelnuovo AF, Dias-da-Costa JS, Diaz A, Dika Z, Djalalinia S, Do HT, Dobson AJ, Donati MB, Donfrancesco C, Donoso SP, Döring A, Dorobantu M, Dorosty AR, Doua K, Drygas W, Duan JL, Duante C, Duleva V, Dulskiene V, Dzerve V, Dziankowska-Zaborszczyk E, Egbagbe EE, Eggertsen R, Eiben G, Ekelund U, El Ati J, Elliott P, Engle-Stone R, Erasmus RT, Erem C, Eriksen L, Eriksson JG, la Peña JE, Evans A, Faeh D, Fall CH, Sant’Angelo VF, Farzadfar F, Felix-Redondo FJ, Ferguson TS, Fernandes RA, Fernández-Bergés D, Ferrante D, Ferrari M, Ferreccio C, Ferrieres J, Finn JD, Fischer K, Flores EM, Föger B, Foo LH, Forslund AS, Forsner M, Fouad HM, Francis DK, Franco M, Franco OH, Frontera G, Fuchs FD, Fuchs SC, Fujita Y, Furusawa T, Gaciong Z, Gafencu M, Galeone D, Galvano F, Garcia-de-la-Hera M, Gareta D, Garnett SP, Gaspoz JM, Gasull M, Gates L, Geiger H, Geleijnse JM, Ghasemian A, Giampaoli S, Gianfagna F, Gill TK, Giovannelli J, Giwercman A, Godos J, Gogen S, Goldsmith RA, Goltzman D, Gonçalves H, González-Leon M, González-Rivas JP, Gonzalez-Gross M, Gottrand F, Graça AP, Graff-Iversen S, Grafnetter D, Grajda A, Grammatikopoulou MG, Gregor RD, Grodzicki T, Grøntved A, Grosso G, Gruden G, Grujic V, Gu D, Gualdi-Russo E, Guallar-Castillón P, Guan OP, Gudmundsson EF, Gudnason V, Guerrero R, Guessous I, Guimaraes AL, Gulliford MC, Gunnlaugsdottir J, Gunter M, Guo X, Guo Y, Gupta PC, Gupta R, Gureje O, Gurzkowska B, Gutierrez L, Gutzwiller F, Hadaegh F, Hadjigeorgiou CA, Si-Ramlee K, Halkjær J, Hambleton IR, Hardy R, Kumar RH, Hassapidou M, Hata J, Hayes AJ, He J, Heidinger-Felso R, Heinen M, Hendriks ME, Henriques A, Cadena LH, Herrala S, Herrera VM, Herter-Aeberli I, Heshmat R, Hihtaniemi IT, Ho SY, Ho SC, Hobbs M, Hofman A, Hopman WM, Horimoto AR, Hormiga CM, Horta BL, Houti L, Howitt C, Htay TT, Htet AS, Htike MMT, Hu Y, Huerta JM, Petrescu CH, Huisman M, Husseini A, Huu CN, Huybrechts I, Hwalla N, Hyska J, Iacoviello L, Iannone AG, Ibarluzea JM, Ibrahim MM, Ikeda N, Ikram MA, Irazola VE, Islam M, Ismail A, Ivkovic V, Iwasaki M, Jackson RT, Jacobs JM, Jaddou H, Jafar T, Jamil KM, Jamrozik K, Janszky I, Jarani J, Jasienska G, Jelakovic A, Jelakovic B, Jennings G, Jeong SL, Jiang CQ, Jiménez-Acosta SM, Joffres M, Johansson M, Jonas JB, Jørgensen T, Joshi P, Jovic DP, Józwiak J, Juolevi A, Jurak G, Jureša V, Kaaks R, Kafatos A, Kajantie EO, Kalter-Leibovici O, Kamaruddin NA, Kapantais E, Karki KB, Kasaeian A, Katz J, Kauhanen J, Kaur P, Kavousi M, Kazakbaeva G, Keil U, Boker LK, Keinänen-Kiukaanniemi S, Kelishadi R, Kelleher C, Kemper HC, Kengne AP, Kerimkulova A, Kersting M, Key T, Khader YS, Khalili D, Khang YH, Khateeb M, Khaw KT, Khouw IM, Kiechl-Kohlendorfer U, Kiechl S, Killewo J, Kim J, Kim YY, Klimont J, Klumbiene J, Knoflach M, Koirala B, Kolle E, Kolsteren P, Korrovits P, Kos J, Koskinen S, Kouda K, Kovacs VA, Kowlessur S, Koziel S, Kratzer W, Kriemler S, Kristensen PL, Krokstad S, Kromhout D, Kruger HS, Kubinova R, Kuciene R, Kuh D, Kujala UM, Kulaga Z, Kumar RK, Kunešová M, Kurjata P, Kusuma YS, Kuulasmaa K, Kyobutungi C, La QN, Laamiri FZ, Laatikainen T, Lachat C, Laid Y, Lam TH, Landrove O, Lanska V, Lappas G, Larijani B, Laugsand LE, Lauria L, Laxmaiah A, Bao KLN, Le TD, Lebanan MAO, Leclercq C, Lee J, Lee J, Lehtimäki T, León-Muñoz LM, Levitt NS, Li Y, Lilly CL, Lim WY, Lima-Costa MF, Lin HH, Lin X, Lind L, Linneberg A, Lissner L, Litwin M, Liu J, Loit HM, Lopes L, Lorbeer R, Lotufo PA, Lozano JE, Luksiene D, Lundqvist A, Lunet N, Lytsy P, Ma G, Ma J, Machado-Coelho GL, Machado-Rodrigues AM, Machi S, Maggi S, Magliano DJ, Magriplis E, Mahaletchumy A, Maire B, Majer M, Makdisse M, Malekzadeh R, Malhotra R, Rao KM, Malyutina S, Manios Y, Mann JI, Manzato E, Margozzini P, Markaki A, Markey O, Marques LP, Marques-Vidal P, Marrugat J, Martin-Prevel Y, Martin R, Martorell R, Martos E, Marventano S, Masoodi SR, Mathiesen EB, Matijasevich A, Matsha TE, Mazur A, Mbanya JCN, McFarlane SR, McGarvey ST, McKee M, McLachlan S, McLean RM, McLean SB, McNulty BA, Yusof SM, Mediene-Benchekor S, Medzioniene J, Meirhaeghe A, Meisfjord J, Meisinger C, Menezes AMB, Menon GR, Mensink GB, Meshram II, Metspalu A, Meyer HE, Mi J, Michaelsen KF, Michels N, Mikkel K, Miller JC, Minderico CS, Miquel JF, Miranda JJ, Mirkopoulou D, Mirrakhimov E, Mišigoj-Durakovic M, Mistretta A, Mocanu V, Modesti PA, Mohamed MK, Mohammad K, Mohammadifard N, Mohan V, Mohanna S, Yusoff MFM, Molbo D, Møllehave LT, Møller NC, Molnár D, Momenan A, Mondo CK, Monterrubio EA, Monyeki KDK, Moon JS, Moreira LB, Morejon A, Moreno LA, Morgan K, Mortensen EL, Moschonis G, Mossakowska M, Mostafa A, Mota J, Mota-Pinto A, Motlagh ME, Motta J, Mu TT, Muc M, Muiesan ML, Müller-Nurasyid M, Murphy N, Mursu J, Murtagh EM, Musil V, Nabipour I, Nagel G, Naidu BM, Nakamura H, Námešná J, Nang EEK, Nangia VB, Nankap M, Narake S, Nardone P, Navarrete-Muñoz EM, Neal WA, Nenko I, Neovius M, Nervi F, Nguyen CT, Nguyen ND, Nguyen QN, Nieto-Martínez RE, Ning G, Ninomiya T, Nishtar S, Noale M, Noboa OA, Norat T, Norie S, Noto D, Nsour MA, O’Reilly D, Obreja G, Oda E, Oehlers G, Oh K, Ohara K, Olafsson Ö, Olinto MTA, Oliveira IO, Oltarzewski M, Omar MA, Onat A, Ong SK, Ono LM, Ordunez P, Ornelas R, Ortiz AP, Osler M, Osmond C, Ostojic SM, Ostovar A, Otero JA, Overvad K, Owusu-Dabo E, Paccaud FM, Padez C, Pahomova E, Pajak A, Palli D, Palloni A, Palmieri L, Pan WH, Panda-Jonas S, Pandey A, Panza F, Papandreou D, Park SW, Parnell WR, Parsaeian M, Pascanu IM, Patel ND, Pecin I, Pednekar MS, Peer N, Peeters PH, Peixoto SV, Peltonen M, Pereira AC, Perez-Farinos N, Pérez CM, Peters A, Petkeviciene J, Petrauskiene A, Peykari N, Pham ST, Pierannunzio D, Pigeot I, Pikhart H, Pilav A, Pilotto L, Pistelli F, Pitakaka F, Piwonska A, Plans-Rubió P, Poh BK, Pohlabeln H, Pop RM, Popovic SR, Porta M, Portegies ML, Posch G, Poulimeneas D, Pouraram H, Pourshams A, Poustchi H, Pradeepa R, Prashant M, Price JF, Puder JJ, Pudule I, Puiu M, Punab M, Qasrawi RF, Qorbani M, Bao TQ, Radic I, Radisauskas R, Rahman M, Rahman M, Raitakari O, Raj M, Rao SR, Ramachandran A, Ramke J, Ramos E, Ramos R, Rampal L, Rampal S, Rascon-Pacheco RA, Redon J, Reganit PFM, Ribas-Barba L, Ribeiro R, Riboli E, Rigo F, de Wit TFR, Rito A, Ritti-Dias RM, Rivera JA, Robinson SM, Robitaille C, Rodrigues D, Rodríguez-Artalejo F, del Cristo Rodriguez-Perez M, Rodríguez-Villamizar LA, Rojas-Martinez R, Rojroongwasinkul N, Romaguera D, Ronkainen K, Rosengren A, Rouse I, Roy JG, Rubinstein A, Rühli FJ, Ruiz-Betancourt BS, Russo P, Rutkowski M, Sabanayagam C, Sachdev HS, Saidi O, Salanave B, Martinez ES, Salmerón D, Salomaa V, Salonen JT, Salvetti M, Sánchez-Abanto J, Sans S, Marina LS, Santos DA, Santos IS, Santos O, dos Santos RN, Santos R, Saramies JL, Sardinha LB, Sarrafzadegan N, Saum KU, Savva S, Savy M, Scazufca M, Rosario AS, Schargrodsky H, Schienkiewitz A, Schipf S, Schmidt CO, Schmidt IM, Schultsz C, Schutte AE, Sein AA, Sen A, Senbanjo IO, Sepanlou SG, Serra-Majem L, Shalnova SA, Sharma SK, Shaw JE, Shibuya K, Shin DW, Shin Y, Shiri R, Siani A, Siantar R, Sibai AM, Silva AM, Silva DAS, Simon M, Simons J, Simons LA, Sjöberg A, Sjöström M, Skovbjerg S, Slowikowska-Hilczer J, Slusarczyk P, Smeeth L, Smith MC, Snijder MB, So HK, Sobngwi E, Söderberg S, Soekatri MY, Solfrizzi V, Sonestedt E, Song Y, Sørensen TI, Soric M, Jérome CS, Soumare A, Spinelli A, Spiroski I, Staessen JA, Stamm H, Starc G, Stathopoulou MG, Staub K, Stavreski B, Steene-Johannessen J, Stehle P, Stein AD, Stergiou GS, Stessman J, Stieber J, Stöckl D, Stocks T, Stokwiszewski J, Stratton G, Stronks K, Strufaldi MW, Suárez-Medina R, Sun CA, Sundström J, Sung YT, Sunyer J, Suriyawongpaisal P, Swinburn BA, Sy RG, Szponar L, Tai ES, Tammesoo ML, Tamosiunas A, Tan EJ, Tang X, Tanser F, Tao Y, Tarawneh MR, Tarp J, Tarqui-Mamani CB, Tautu OF, Braunerová RT, Taylor A, Tchibindat F, Theobald H, Theodoridis X, Thijs L, Thuesen BH, Tjonneland A, Tolonen HK, Tolstrup JS, Topbas M, Topór-Madry R, Tormo MJ, Tornaritis MJ, Torrent M, Toselli S, Traissac P, Trichopoulos D, Trichopoulou A, Trinh OT, Trivedi A, Tshepo L, Tsigga M, Tsugane S, Tulloch-Reid MK, Tullu F, Tuomainen TP, Tuomilehto J, Turley ML, Tynelius P, Tzotzas T, Tzourio C, Ueda P, Ugel EE, Ukoli FA, Ulmer H, Unal B, Uusitalo HM, Valdivia G, Vale S, Valvi D, van der Schouw YT, Van Herck K, Van Minh H, van Rossem L, Van Schoor NM, van Valkengoed IG, Vanderschueren D, Vanuzzo D, Vatten L, Vega T, Veidebaum T, Velasquez-Melendez G, Velika B, Veronesi G, Verschuren WM, Victora CG, Viegi G, Viet L, Viikari-Juntura E, Vineis P, Vioque J, Virtanen JK, Visvikis-Siest S, Viswanathan B, Vlasoff T, Vollenweider P, Völzke H, Voutilainen S, Vrijheid M, Wade AN, Wagner A, Waldhör T, Walton J, Bebakar WMW, Mohamud WNW, Wanderley RS, Wang MD, Wang Q, Wang YX, Wang YW, Wannamethee SG, Wareham N, Weber A, Wedderkopp N, Weerasekera D, Whincup PH, Widhalm K, Widyahening IS, Wiecek A, Wijga AH, Wilks RJ, Willeit J, Willeit P, Wilsgaard T, Wojtyniak B, Wong-McClure RA, Wong JY, Wong JE, Wong TY, Woo J, Woodward M, Wu FC, Wu J, Wu S, Xu H, Xu L, Yamborisut U, Yan W, Yang X, Yardim N, Ye X, Yiallouros PK, Yngve A, Yoshihara A, You QS, Younger-Coleman NO, Yusoff F, Yusoff MFM, Zaccagni L, Zafiropulos V, Zainuddin AA, Zambon S, Zampelas A, Zamrazilová H, Zdrojewski T, Zeng Y, Zhao D, Zhao W, Zheng W, Zheng Y, Zholdin B, Zhou M, Zhu D, Zhussupov B, Zimmermann E, Cisneros JZ, Bentham J, Di Cesare M, Bilano V, Bixby H, Zhou B, Stevens GA, Riley LM, Taddei C, Hajifathalian K, Lu Y, Savin S, Cowan MJ, Paciorek CJ, Chirita-Emandi A, Hayes AJ, Katz J, Kelishadi R, Kengne AP, Khang YH, Laxmaiah A, Li Y, Ma J, Miranda JJ, Mostafa A, Neovius M, Padez C, Rampal L, Zhu A, Bennett JE, Danaei G, Bhutta ZA, Ezzati M. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: A pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet. 2017;390:2627–2642. doi: 10.1016/S0140-6736(17)32129-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Ahima RS. Connecting obesity, aging and diabetes. Nature Medicine. 2009;15:996–997. doi: 10.1038/nm0909-996. [DOI] [PubMed] [Google Scholar]
  3. Aronis KN, Sahin-Efe A, Chamberland JP, Spiro A, Vokonas P, Mantzoros CS. Chemerin levels as predictor of acute coronary events: A case–control study nested within the Veterans Affairs normative aging study. Metabolism. 2014;63:760–766. doi: 10.1016/j.metabol.2014.02.013. [DOI] [PubMed] [Google Scholar]
  4. Ashtary-Larky D, Kashkooli S, Bagheri R, Lamuchi-Deli N, Alipour M, Mombaini D, Baker JS, Ramezani Ahmadi A, Wong A. The effect of exercise training on serum concentrations of chemerin in patients with metabolic diseases: a systematic review and meta-analysis. Archives of Physiology and Biochemistry. 2021;1:1–10. doi: 10.1080/13813455.2021.1892149. [DOI] [PubMed] [Google Scholar]
  5. Ballarini T, Melo van Lent D, Brunner J, Schröder A, Wolfsgruber S, Altenstein S, Brosseron F, Buerger K, Dechent P, Dobisch L, Duzel E, Ertl-Wagner B, Fliessbach K, Freiesleben SD, Frommann I, Glanz W, Hauser D, Haynes JD, Heneka MT, Janowitz D, Kilimann I, Laske C, Maier F, Metzger CD, Munk M, Perneczky R, Peters O, Priller J, Ramirez A, Rauchmann B, Roy N, Scheffler K, Schneider A, Spottke A, Spruth EJ, Teipel SJ, Vukovich R, Wiltfang J, Jessen F, Wagner M, DELCODE study group Mediterranean diet, alzheimer disease biomarkers and brain atrophy in old age. Neurology. 2021;96:e2920–e3932. doi: 10.1212/WNL.0000000000012067. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bashyam VM, Erus G, Doshi J, Habes M, Nasrallah I, Truelove-Hill M, Srinivasan D, Mamourian L, Pomponio R, Fan Y, Launer LJ, Masters CL, Maruff P, Zhuo C, Völzke H, Johnson SC, Fripp J, Koutsouleris N, Satterthwaite TD, Wolf D, Gur RE, Gur RC, Morris J, Albert MS, Grabe HJ, Resnick S, Bryan RN, Wolk DA, Shou H, Davatzikos C. Mri signatures of brain age and disease over the lifespan based on a deep brain network and 14 468 individuals worldwide. Brain. 2020;143:2312–2324. doi: 10.1093/brain/awaa160. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Bassett DS, Wymbs NF, Porter MA, Mucha PJ, Carlson JM, Grafton ST. Dynamic reconfiguration of human brain networks during learning. PNAS. 2011;108:7641–7646. doi: 10.1073/pnas.1018985108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Beck D, de Lange A-MG, Alnæs D, Maximov II, Pedersen ML, Leinhard OD, Linge J, Simon R, Richard G, Ulrichsen KM, Dørum ES, Kolskår KK, Sanders AM, Winterton A, Gurholt TP, Kaufmann T, Steen NE, Nordvik JE, Andreassen OA, Westlye LT. Adipose tissue distribution from body MRI is associated with cross-sectional and longitudinal brain age in adults. NeuroImage. Clinical. 2022;33:102949. doi: 10.1016/j.nicl.2022.102949. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Behzadi Y, Restom K, Liau J, Liu TT. A component based noise correction method (compcor) for BOLD and perfusion based fmri. NeuroImage. 2007;37:90–101. doi: 10.1016/j.neuroimage.2007.04.042. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. Journal of the Royal Statistical Society. 1995;57:289–300. doi: 10.1111/j.2517-6161.1995.tb02031.x. [DOI] [Google Scholar]
  11. Bethlehem RAI, Seidlitz J, White SR, Vogel JW, Anderson KM, Adamson C, Adler S, Alexopoulos GS, Anagnostou E, Areces-Gonzalez A, Astle DE, Auyeung B, Ayub M, Bae J, Ball G, Baron-Cohen S, Beare R, Bedford SA, Benegal V, Beyer F, Blangero J, Blesa Cábez M, Boardman JP, Borzage M, Bosch-Bayard JF, Bourke N, Calhoun VD, Chakravarty MM, Chen C, Chertavian C, Chetelat G, Chong YS, Cole JH, Corvin A, Costantino M, Courchesne E, Crivello F, Cropley VL, Crosbie J, Crossley N, Delarue M, Delorme R, Desrivieres S, Devenyi GA, Di Biase MA, Dolan R, Donald KA, Donohoe G, Dunlop K, Edwards AD, Elison JT, Ellis CT, Elman JA, Eyler L, Fair DA, Feczko E, Fletcher PC, Fonagy P, Franz CE, Galan-Garcia L, Gholipour A, Giedd J, Gilmore JH, Glahn DC, Goodyer IM, Grant PE, Groenewold NA, Gunning FM, Gur RE, Gur RC, Hammill CF, Hansson O, Hedden T, Heinz A, Henson RN, Heuer K, Hoare J, Holla B, Holmes AJ, Holt R, Huang H, Im K, Ipser J, Jack CR, Jackowski AP, Jia T, Johnson KA, Jones PB, Jones DT, Kahn RS, Karlsson H, Karlsson L, Kawashima R, Kelley EA, Kern S, Kim KW, Kitzbichler MG, Kremen WS, Lalonde F, Landeau B, Lee S, Lerch J, Lewis JD, Li J, Liao W, Liston C, Lombardo MV, Lv J, Lynch C, Mallard TT, Marcelis M, Markello RD, Mathias SR, Mazoyer B, McGuire P, Meaney MJ, Mechelli A, Medic N, Misic B, Morgan SE, Mothersill D, Nigg J, Ong MQW, Ortinau C, Ossenkoppele R, Ouyang M, Palaniyappan L, Paly L, Pan PM, Pantelis C, Park MM, Paus T, Pausova Z, Paz-Linares D, Pichet Binette A, Pierce K, Qian X, Qiu J, Qiu A, Raznahan A, Rittman T, Rodrigue A, Rollins CK, Romero-Garcia R, Ronan L, Rosenberg MD, Rowitch DH, Salum GA, Satterthwaite TD, Schaare HL, Schachar RJ, Schultz AP, Schumann G, Schöll M, Sharp D, Shinohara RT, Skoog I, Smyser CD, Sperling RA, Stein DJ, Stolicyn A, Suckling J, Sullivan G, Taki Y, Thyreau B, Toro R, Traut N, Tsvetanov KA, Turk-Browne NB, Tuulari JJ, Tzourio C, Vachon-Presseau É, Valdes-Sosa MJ, Valdes-Sosa PA, Valk SL, van Amelsvoort T, Vandekar SN, Vasung L, Victoria LW, Villeneuve S, Villringer A, Vértes PE, Wagstyl K, Wang YS, Warfield SK, Warrier V, Westman E, Westwater ML, Whalley HC, Witte AV, Yang N, Yeo B, Yun H, Zalesky A, Zar HJ, Zettergren A, Zhou JH, Ziauddeen H, Zugman A, Zuo XN, Bullmore ET, Alexander-Bloch AF, 3R-BRAIN. AIBL. Alzheimer’s Disease Neuroimaging Initiative. Alzheimer’s Disease Repository Without Borders Investigators. CALM Team. Cam-CAN. CCNP. COBRE. cVEDA. ENIGMA Developmental Brain Age Working Group. Developing Human Connectome Project. FinnBrain. Harvard Aging Brain Study. IMAGEN. KNE96. Mayo Clinic Study of Aging. NSPN. POND. PREVENT-AD Research Group. VETSA Brain charts for the human lifespan. Nature. 2022;604:525–533. doi: 10.1038/s41586-022-04554-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Beyer F, Kharabian Masouleh S, Huntenburg JM, Lampe L, Luck T, Riedel-Heller SG, Loeffler M, Schroeter ML, Stumvoll M, Villringer A, Witte AV. Higher body mass index is associated with reduced posterior default mode connectivity in older adults. Human Brain Mapping. 2017;38:3502–3515. doi: 10.1002/hbm.23605. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Blüher M, Rudich A, Klöting N, Golan R, Henkin Y, Rubin E, Schwarzfuchs D, Gepner Y, Stampfer MJ, Fiedler M, Thiery J, Stumvoll M, Shai I. Two patterns of adipokine and other biomarker dynamics in a long-term weight loss intervention. Diabetes Care. 2012;35:342–349. doi: 10.2337/dc11-1267. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Brusini I, MacNicol E, Kim E, Smedby Ö, Wang C, Westman E, Veronese M, Turkheimer F, Cash D. MRI-derived brain age as a biomarker of ageing in rats: Validation using a healthy lifestyle intervention. Neurobiology of Aging. 2022;109:204–215. doi: 10.1016/j.neurobiolaging.2021.10.004. [DOI] [PubMed] [Google Scholar]
  15. Cameron C, Sharad S, Brian C, Ranjeet K, Satrajit G, Chaogan Y, Qingyang L, Daniel L, Joshua V, Randal B, Stanley C, Maarten M, Clare K, Adriana DM, Francisco C, Michael M. Towards automated analysis of connectomes: The configurable pipeline for the analysis of connectomes (C-PAC) Frontiers in Neuroinformatics. 2013;7:42. doi: 10.3389/conf.fninf.2013.09.00042. [DOI] [Google Scholar]
  16. Centers for Disease Control and Prevention Assessing Your Weight | Healthy Weight, Nutrition, and Physical Activity. CDC. 2020. [February 8, 2023]. https://www.cdc.gov/healthyweight/assessing/index.html
  17. Chang AY, Skirbekk VF, Tyrovolas S, Kassebaum NJ, Dieleman JL. Measuring population ageing: an analysis of the global burden of disease study 2017. The Lancet Public Health. 2019;4:e159–e167. doi: 10.1016/S2468-2667(19)30019-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Cole JH, Franke K. Predicting age using neuroimaging: innovative brain ageing biomarkers. Trends in Neurosciences. 2017;40:681–690. doi: 10.1016/j.tins.2017.10.001. [DOI] [PubMed] [Google Scholar]
  19. Cole JH, Ritchie SJ, Bastin ME, Valdés Hernández MC, Muñoz Maniega S, Royle N, Corley J, Pattie A, Harris SE, Zhang Q, Wray NR, Redmond P, Marioni RE, Starr JM, Cox SR, Wardlaw JM, Sharp DJ, Deary IJ. Brain age predicts mortality. Molecular Psychiatry. 2018;23:1385–1392. doi: 10.1038/mp.2017.62. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Craig MH, Margaret DC, Cheryl DF, Cynthia LO. Prevalence of obesity and severe obesity among adults: United States, 2017–2018. 2020. [May 10, 2022]. https://www.cdc.gov/nchs/products/databriefs/db360.html
  21. Daoust J, Schaffer J, Zeighami Y, Dagher A, García-García I, Michaud A. White matter integrity differences in obesity: A meta-analysis of diffusion tensor imaging studies. Neuroscience and Biobehavioral Reviews. 2021;129:133–141. doi: 10.1016/j.neubiorev.2021.07.020. [DOI] [PubMed] [Google Scholar]
  22. de Lange AG, Anatürk M, Rokicki J, Han LKM, Franke K, Alnæs D, Ebmeier KP, Draganski B, Kaufmann T, Westlye LT, Hahn T, Cole JH. Mind the gap: Performance metric evaluation in brain‐age prediction. Human Brain Mapping. 2022;43:3113–3129. doi: 10.1002/hbm.25837. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Dosenbach NUF, Nardos B, Cohen AL, Fair DA, Power JD, Church JA, Nelson SM, Wig GS, Vogel AC, Lessov-Schlaggar CN, Barnes KA, Dubis JW, Feczko E, Coalson RS, Pruett JR, Barch DM, Petersen SE, Schlaggar BL. Prediction of individual brain maturity using fmri. Science. 2010;329:1358–1361. doi: 10.1126/science.1194144. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Doucet GE, Rasgon N, McEwen BS, Micali N, Frangou S. Elevated body mass index is associated with increased integration and reduced cohesion of sensory-driven and internally guided resting-state functional brain networks. Cerebral Cortex. 2018;28:988–997. doi: 10.1093/cercor/bhx008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Dunlop K, Victoria LW, Downar J, Gunning FM, Liston C. Accelerated brain aging predicts impulsivity and symptom severity in depression. Neuropsychopharmacology. 2021;46:911–919. doi: 10.1038/s41386-021-00967-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Erickson KI, Voss MW, Prakash RS, Basak C, Szabo A, Chaddock L, Kim JS, Heo S, Alves H, White SM, Wojcicki TR, Mailey E, Vieira VJ, Martin SA, Pence BD, Woods JA, McAuley E, Kramer AF. Exercise training increases size of hippocampus and improves memory. PNAS. 2011;108:3017–3022. doi: 10.1073/pnas.1015950108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Ernst MC, Sinal CJ. Chemerin: At the crossroads of inflammation and obesity. Trends in Endocrinology and Metabolism. 2010;21:660–667. doi: 10.1016/j.tem.2010.08.001. [DOI] [PubMed] [Google Scholar]
  28. Espeland MA, Erickson K, Neiberg RH, Jakicic JM, Wadden TA, Wing RR, Desiderio L, Erus G, Hsieh M-K, Davatzikos C, Maschak-Carey BJ, Laurienti PJ, Demos-McDermott K, Bryan RN, Action for Health in Diabetes Brain Magnetic Resonance Imaging Ancillary Study Research Group Brain and white matter hyperintensity volumes after 10 years of random assignment to lifestyle intervention. Diabetes Care. 2016;39:764–771. doi: 10.2337/dc15-2230. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Esteban O, Markiewicz CJ, Blair RW, Moodie CA, Isik AI, Erramuzpe A, Kent JD, Goncalves M, DuPre E, Snyder M, Oya H, Ghosh SS, Wright J, Durnez J, Poldrack RA, Gorgolewski KJ. fMRIPrep: A robust preprocessing pipeline for functional MRI. Nature Methods. 2019;16:111–116. doi: 10.1038/s41592-018-0235-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Estruch R, Ros E, Salas-Salvadó J, Covas M-I, Corella D, Arós F, Gómez-Gracia E, Ruiz-Gutiérrez V, Fiol M, Lapetra J, Lamuela-Raventos RM, Serra-Majem L, Pintó X, Basora J, Muñoz MA, Sorlí JV, Martínez JA, Martínez-González MA. Primary prevention of cardiovascular disease with a Mediterranean diet. New England Journal of Medicine. 2013;368:1279–1290. doi: 10.1056/NEJMoa1200303. [DOI] [PubMed] [Google Scholar]
  31. Fabian P, Michel V, Grisel O. Scikit-learn: machine learning in python. Journal of Machine Learning Research: JMLR. 2011;12:2825–2830. doi: 10.1007/s13398-014-0173-7.2. [DOI] [Google Scholar]
  32. Farruggia MC, Small DM. Effects of adiposity and metabolic dysfunction on cognition: A review. Physiology & Behavior. 2019;208:112578. doi: 10.1016/j.physbeh.2019.112578. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Ferland DJ, Mullick AE, Watts SW. Chemerin as A driver of hypertension: A consideration. American Journal of Hypertension. 2020;33:975–986. doi: 10.1093/ajh/hpaa084. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Fischl B, Sereno MI, Dale AM. Cortical surface-based analysis II: inflation, flattening, and a surface-based coordinate system. NeuroImage. 1999;9:195–207. doi: 10.1006/nimg.1998.0396. [DOI] [PubMed] [Google Scholar]
  35. Fjell AM, Sneve MH, Grydeland H, Storsve AB, Walhovd KB. The disconnected brain and executive function decline in aging. Cerebral Cortex. 2017;27:2303–2317. doi: 10.1093/cercor/bhw082. [DOI] [PubMed] [Google Scholar]
  36. Fraga MF. Genetic and epigenetic regulation of aging. Current Opinion in Immunology. 2009;21:446–453. doi: 10.1016/j.coi.2009.04.003. [DOI] [PubMed] [Google Scholar]
  37. Franke K, Ristow M, Gaser C. Gender-specific impact of personal health parameters on individual brain aging in cognitively unimpaired elderly subjects. Frontiers in Aging Neuroscience. 2014;6:94. doi: 10.3389/fnagi.2014.00094. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Franke K, Gaser C. Ten years of brainage as a neuroimaging biomarker of brain aging: what insights have we gained? Frontiers in Neurology. 2019;10:789. doi: 10.3389/fneur.2019.00789. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Frasca D, Blomberg BB, Paganelli R. Aging, obesity, and inflammatory age-related diseases. Frontiers in Immunology. 2017;8:1745. doi: 10.3389/fimmu.2017.01745. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Gampawar P, Schmidt R, Schmidt H. Leukocyte telomere length is related to brain parenchymal fraction and attention/speed in the elderly: results of the austrian stroke prevention study. Frontiers in Psychiatry. 2020;11:100. doi: 10.3389/fpsyt.2020.00100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. García-Casares N, Bernal-López M, Roé-Vellvé N, Gutiérrez-Bedmar M, Fernández-García J, García-Arnés J, Ramos-Rodriguez J, Alfaro F, Santamaria-Fernández S, Steward T, Jiménez-Murcia S, Garcia-Garcia I, Valdivielso P, Fernández-Aranda F, Tinahones F, Gómez-Huelgas R. Brain functional connectivity is modified by a hypocaloric Mediterranean diet and physical activity in obese women. Nutrients. 2017;9:685. doi: 10.3390/nu9070685. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. García-García I, Michaud A, Dadar M, Zeighami Y, Neseliler S, Collins DL, Evans AC, Dagher A. Neuroanatomical differences in obesity: Meta-analytic findings and their validation in an independent dataset. International Journal of Obesity. 2019;43:943–951. doi: 10.1038/s41366-018-0164-4. [DOI] [PubMed] [Google Scholar]
  43. Gardener SL, Rainey-Smith SR. The role of nutrition in cognitive function and brain ageing in the elderly. Current Nutrition Reports. 2018;7:139–149. doi: 10.1007/s13668-018-0229-y. [DOI] [PubMed] [Google Scholar]
  44. Gepner Y, Shelef I, Schwarzfuchs D, Zelicha H, Tene L, Yaskolka Meir A, Tsaban G, Cohen N, Bril N, Rein M, Serfaty D, Kenigsbuch S, Komy O, Wolak A, Chassidim Y, Golan R, Avni-Hassid H, Bilitzky A, Sarusi B, Goshen E, Shemesh E, Henkin Y, Stumvoll M, Blüher M, Thiery J, Ceglarek U, Rudich A, Stampfer MJ, Shai I. Effect of distinct lifestyle interventions on mobilization of fat storage pools: Central magnetic resonance imaging randomized controlled trial. Circulation. 2018;137:1143–1157. doi: 10.1161/CIRCULATIONAHA.117.030501. [DOI] [PubMed] [Google Scholar]
  45. Ghareeb DA, Hafez HS, Hussien HM, Kabapy NF. Non-Alcoholic fatty liver induces insulin resistance and metabolic disorders with development of brain damage and dysfunction. Metabolic Brain Disease. 2011;26:253–267. doi: 10.1007/s11011-011-9261-y. [DOI] [PubMed] [Google Scholar]
  46. Gonneaud J, Baria AT, Pichet Binette A, Gordon BA, Chhatwal JP, Cruchaga C, Jucker M, Levin J, Salloway S, Farlow M, Gauthier S, Benzinger TLS, Morris JC, Bateman RJ, Breitner JCS, Poirier J, Vachon-Presseau E, Villeneuve S, Alzheimer’s Disease Neuroimaging Initiative. Dominantly Inherited Alzheimer Network Study Group. Pre-symptomatic Evaluation of Experimental or Novel Treatments for Alzheimer’s Disease Research Group Accelerated functional brain aging in pre-clinical familial alzheimer’s disease. Nature Communications. 2021;12:5346. doi: 10.1038/s41467-021-25492-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC, Spertus JA, Costa F, American Heart Association. National Heart, Lung, and Blood Institute Diagnosis and management of the metabolic syndrome: an american heart association/national heart, lung, and blood institute scientific statement. Circulation. 2005;112:2735–2752. doi: 10.1161/CIRCULATIONAHA.105.169404. [DOI] [PubMed] [Google Scholar]
  48. Gupta A, Osadchiy V, Mayer EA. Brain-gut-microbiome interactions in obesity and food addiction. Nature Reviews. Gastroenterology & Hepatology. 2020;17:655–672. doi: 10.1038/s41575-020-0341-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Hamczyk MR, Nevado RM, Barettino A, Fuster V, Andrés V. Biological versus chronological aging: JACC focus seminar. Journal of the American College of Cardiology. 2020;75:919–930. doi: 10.1016/j.jacc.2019.11.062. [DOI] [PubMed] [Google Scholar]
  50. Heister D, Brewer JB, Magda S, Blennow K, McEvoy LK, Alzheimer’s Disease Neuroimaging Initiative Predicting MCI outcome with clinically available MRI and CSF biomarkers. Neurology. 2011;77:1619–1628. doi: 10.1212/WNL.0b013e3182343314. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Helfer G, Wu QF. Chemerin: A multifaceted adipokine involved in metabolic disorders. The Journal of Endocrinology. 2018;238:R79–R94. doi: 10.1530/JOE-18-0174. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Hilger K, Winter NR, Leenings R, Sassenhagen J, Hahn T, Basten U, Fiebach CJ. Predicting intelligence from brain gray matter volume. Brain Structure & Function. 2020;225:2111–2129. doi: 10.1007/s00429-020-02113-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Honey CJ, Kötter R, Breakspear M, Sporns O. Network structure of cerebral cortex shapes functional connectivity on multiple time scales. PNAS. 2007;104:10240–10245. doi: 10.1073/pnas.0701519104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Hottman DA, Chernick D, Cheng S, Wang Z, Li L. HDL and cognition in neurodegenerative disorders. Neurobiology of Disease. 2014;72 Pt A:22–36. doi: 10.1016/j.nbd.2014.07.015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Hu HH, Kim HW, Nayak KS, Goran MI. Comparison of fat-water MRI and single-voxel MRS in the assessment of hepatic and pancreatic fat fractions in humans. Obesity. 2010;18:841–847. doi: 10.1038/oby.2009.352. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Jack CR, Wiste HJ, Weigand SD, Therneau TM, Lowe VJ, Knopman DS, Gunter JL, Senjem ML, Jones DT, Kantarci K, Machulda MM, Mielke MM, Roberts RO, Vemuri P, Reyes DA, Petersen RC. Defining imaging biomarker cut points for brain aging and Alzheimer’s disease. Alzheimer’s & Dementia. 2017;13:205–216. doi: 10.1016/j.jalz.2016.08.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Jirsaraie RJ, Kaufmann T, Bashyam V, Erus G, Luby JL, Westlye LT, Davatzikos C, Barch DM, Sotiras A. Benchmarking the generalizability of brain age models: challenges posed by scanner variance and prediction bias. Human Brain Mapping. 2023;44:1118–1128. doi: 10.1002/hbm.26144. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Kaplan A, Zelicha H, Yaskolka Meir A, Rinott E, Tsaban G, Levakov G, Prager O, Salti M, Yovell Y, Ofer J, Huhn S, Beyer F, Witte V, Villringer A, Meiran N, B Emesh T, Kovacs P, von Bergen M, Ceglarek U, Blüher M, Stumvoll M, Hu FB, Stampfer MJ, Friedman A, Shelef I, Avidan G, Shai I. The effect of a high-polyphenol mediterranean diet (green-MED) combined with physical activity on age-related brain atrophy: The dietary intervention randomized controlled trial polyphenols unprocessed study (DIRECT PLUS) The American Journal of Clinical Nutrition. 2022;115:1270–1281. doi: 10.1093/ajcn/nqac001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Kolenic M, Franke K, Hlinka J, Matejka M, Capkova J, Pausova Z, Uher R, Alda M, Spaniel F, Hajek T. Obesity, dyslipidemia and brain age in first-episode psychosis. Journal of Psychiatric Research. 2018;99:151–158. doi: 10.1016/j.jpsychires.2018.02.012. [DOI] [PubMed] [Google Scholar]
  60. Koutsouleris N, Davatzikos C, Borgwardt S, Gaser C, Bottlender R, Frodl T, Falkai P, Riecher-Rössler A, Möller H-J, Reiser M, Pantelis C, Meisenzahl E. Accelerated brain aging in schizophrenia and beyond: A neuroanatomical marker of psychiatric disorders. Schizophrenia Bulletin. 2014;40:1140–1153. doi: 10.1093/schbul/sbt142. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Kukuk GM, Hittatiya K, Sprinkart AM, Eggers H, Gieseke J, Block W, Moeller P, Willinek WA, Spengler U, Trebicka J, Fischer H-P, Schild HH, Träber F. Comparison between modified Dixon MRI techniques, MR spectroscopic relaxometry, and different histologic quantification methods in the assessment of hepatic steatosis. European Radiology. 2015;25:2869–2879. doi: 10.1007/s00330-015-3703-6. [DOI] [PubMed] [Google Scholar]
  62. Kullmann S, Schweizer F, Veit R, Fritsche A, Preissl H. Compromised white matter integrity in obesity. Obesity Reviews. 2015;16:273–281. doi: 10.1111/obr.12248. [DOI] [PubMed] [Google Scholar]
  63. Labenz C, Kostev K, Kaps L, Galle PR, Schattenberg JM. Incident dementia in elderly patients with nonalcoholic fatty liver disease in Germany. Digestive Diseases and Sciences. 2021;66:3179–3185. doi: 10.1007/s10620-020-06644-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Leigh SJ, Morris MJ. Diet, inflammation and the gut microbiome: mechanisms for obesity-associated cognitive impairment. Biochimica et Biophysica Acta. Molecular Basis of Disease. 2020;1866:165767. doi: 10.1016/j.bbadis.2020.165767. [DOI] [PubMed] [Google Scholar]
  65. Levakov G, Rosenthal G, Shelef I, Raviv TR, Avidan G. From a deep learning model back to the brain-identifying regional predictors and their relation to aging. Human Brain Mapping. 2020;41:3235–3252. doi: 10.1002/hbm.25011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Levakov G, Faskowitz J, Avidan G, Sporns O. Mapping individual differences across brain network structure to function and behavior with connectome embedding. NeuroImage. 2021;242:118469. doi: 10.1016/j.neuroimage.2021.118469. [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Levakov G, Kaplan A, Yaskolka Meir A, Rinott E, Tsaban G, Zelicha H, Bluher M, Ceglarek U, Stumvoll M, Shelef I, Avidan G. The effect of weight loss following 18 months of lifestyle intervention on brain age assessed with resting-state functional Connectivity. swh:1:rev:cc09850f6667fe687b07527596c65813a4abd813Software Heritage. 2023 doi: 10.7554/eLife.83604. https://archive.softwareheritage.org/swh:1:dir:4e5c0028d87ebe463b89dead3df34c830cd26985;origin=https://github.com/GidLev/functional_brain_aging;visit=swh:1:snp:390e43ea7413d63ded6ee24f36827a78fdf8fbd8;anchor=swh:1:rev:cc09850f6667fe687b07527596c65813a4abd813 [DOI] [PMC free article] [PubMed]
  68. Liem F, Varoquaux G, Kynast J, Beyer F, Kharabian Masouleh S, Huntenburg JM, Lampe L, Rahim M, Abraham A, Craddock RC, Riedel-Heller S, Luck T, Loeffler M, Schroeter ML, Witte AV, Villringer A, Margulies DS. Predicting brain-age from multimodal imaging data captures cognitive impairment. NeuroImage. 2017;148:179–188. doi: 10.1016/j.neuroimage.2016.11.005. [DOI] [PubMed] [Google Scholar]
  69. Lopez KC, Kandala S, Marek S, Barch DM. Development of network topology and functional connectivity of the prefrontal cortex. Cerebral Cortex. 2020;30:2489–2505. doi: 10.1093/cercor/bhz255. [DOI] [PubMed] [Google Scholar]
  70. Lowe CJ, Reichelt AC, Hall PA. The prefrontal cortex and obesity: A health neuroscience perspective. Trends in Cognitive Sciences. 2019;23:349–361. doi: 10.1016/j.tics.2019.01.005. [DOI] [PubMed] [Google Scholar]
  71. McFadden KL, Cornier MA, Melanson EL, Bechtell JL, Tregellas JR. Effects of exercise on resting-state default mode and salience network activity in overweight/obese adults. Neuroreport. 2013;24:866–871. doi: 10.1097/WNR.0000000000000013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Mišić B, Sporns O. From regions to connections and networks: New bridges between brain and behavior. Current Opinion in Neurobiology. 2016;40:1–7. doi: 10.1016/j.conb.2016.05.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Mora F. Successful brain aging: Plasticity, environmental enrichment, and lifestyle. Dialogues in Clinical Neuroscience. 2013;15:45–52. doi: 10.31887/DCNS.2013.15.1/fmora. [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Nho K, Kueider-Paisley A, Ahmad S, MahmoudianDehkordi S, Arnold M, Risacher SL, Louie G, Blach C, Baillie R, Han X, Kastenmüller G, Trojanowski JQ, Shaw LM, Weiner MW, Doraiswamy PM, van Duijn C, Saykin AJ, Kaddurah-Daouk R, Alzheimer’s Disease Neuroimaging Initiative and the Alzheimer Disease Metabolomics Consortium Association of altered liver enzymes with alzheimer disease diagnosis, cognition, neuroimaging measures, and cerebrospinal fluid biomarkers. JAMA Network Open. 2019;2:e197978. doi: 10.1001/jamanetworkopen.2019.7978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Niedernhofer LJ, Gurkar AU, Wang Y, Vijg J, Hoeijmakers JHJ, Robbins PD. Nuclear genomic instability and aging. Annual Review of Biochemistry. 2018;87:295–322. doi: 10.1146/annurev-biochem-062917-012239. [DOI] [PubMed] [Google Scholar]
  76. Nooner KB, Colcombe SJ, Tobe RH, Mennes M, Benedict MM, Moreno AL, Panek LJ, Brown S, Zavitz ST, Li Q, Sikka S, Gutman D, Bangaru S, Schlachter RT, Kamiel SM, Anwar AR, Hinz CM, Kaplan MS, Rachlin AB, Adelsberg S, Cheung B, Khanuja R, Yan C, Craddock CC, Calhoun V, Courtney W, King M, Wood D, Cox CL, Kelly AMC, Di Martino A, Petkova E, Reiss PT, Duan N, Thomsen D, Biswal B, Coffey B, Hoptman MJ, Javitt DC, Pomara N, Sidtis JJ, Koplewicz HS, Castellanos FX, Leventhal BL, Milham MP. The NKI-rockland sample: A model for accelerating the pace of discovery science in psychiatry. Frontiers in Neuroscience. 2012;6:152. doi: 10.3389/fnins.2012.00152. [DOI] [PMC free article] [PubMed] [Google Scholar]
  77. Park MH, Sovio U, Viner RM, Hardy RJ, Kinra S, Li S. Overweight in childhood, adolescence and adulthood and cardiovascular risk in later life: Pooled analysis of three British birth cohorts. PLOS ONE. 2013;8:e70684. doi: 10.1371/journal.pone.0070684. [DOI] [PMC free article] [PubMed] [Google Scholar]
  78. Parsons N, Steward T, Clohesy R, Almgren H, Duehlmeyer L. A systematic review of resting-state functional connectivity in obesity: Refining current neurobiological frameworks and methodological considerations moving forward. Reviews in Endocrine & Metabolic Disorders. 2022;23:861–879. doi: 10.1007/s11154-021-09665-x. [DOI] [PubMed] [Google Scholar]
  79. Pedditzi E, Peters R, Beckett N. The risk of overweight/obesity in mid-life and late life for the development of dementia: A systematic review and meta-analysis of longitudinal studies. Age and Ageing. 2016;45:14–21. doi: 10.1093/ageing/afv151. [DOI] [PubMed] [Google Scholar]
  80. Power JD, Mitra A, Laumann TO, Snyder AZ, Schlaggar BL, Petersen SE. Methods to detect, characterize, and remove motion artifact in resting state fMRI. NeuroImage. 2014;84:320–341. doi: 10.1016/j.neuroimage.2013.08.048. [DOI] [PMC free article] [PubMed] [Google Scholar]
  81. Pugazhenthi S, Qin L, Reddy PH. Common neurodegenerative pathways in obesity, diabetes, and Alzheimer’s disease. Biochimica et Biophysica Acta - Molecular Basis of Disease. 2017;1863:1037–1045. doi: 10.1016/j.bbadis.2016.04.017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  82. Rinott E, Youngster I, Yaskolka Meir A, Tsaban G, Zelicha H, Kaplan A, Knights D, Tuohy K, Fava F, Scholz MU, Ziv O, Reuven E, Tirosh A, Rudich A, Blüher M, Stumvoll M, Ceglarek U, Clement K, Koren O, Wang DD, Hu FB, Stampfer MJ, Shai I. Effects of diet-modulated autologous fecal microbiota transplantation on weight regain. Gastroenterology. 2021;160:158–173. doi: 10.1053/j.gastro.2020.08.041. [DOI] [PMC free article] [PubMed] [Google Scholar]
  83. Ronan L, Alexander-Bloch AF, Wagstyl K, Farooqi S, Brayne C, Tyler LK, Cam-CAN. Fletcher PC. Obesity associated with increased brain age from midlife. Neurobiology of Aging. 2016;47:63–70. doi: 10.1016/j.neurobiolaging.2016.07.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  84. Rubinov M, Sporns O. Complex network measures of brain connectivity: Uses and interpretations. NeuroImage. 2010;52:1059–1069. doi: 10.1016/j.neuroimage.2009.10.003. [DOI] [PubMed] [Google Scholar]
  85. Sala-Llonch R, Bartrés-Faz D, Junqué C. Reorganization of brain networks in aging: A review of functional connectivity studies. Frontiers in Psychology. 2015;6:663. doi: 10.3389/fpsyg.2015.00663. [DOI] [PMC free article] [PubMed] [Google Scholar]
  86. Salvestrini V, Sell C, Lorenzini A. Obesity may accelerate the aging process. Frontiers in Endocrinology. 2019;10:266. doi: 10.3389/fendo.2019.00266. [DOI] [PMC free article] [PubMed] [Google Scholar]
  87. Schaefer A, Kong R, Gordon EM, Laumann TO, Zuo X-N, Holmes AJ, Eickhoff SB, Yeo BTT. Local-global parcellation of the human cerebral cortex from intrinsic functional connectivity MRI. Cerebral Cortex. 2018;28:3095–3114. doi: 10.1093/cercor/bhx179. [DOI] [PMC free article] [PubMed] [Google Scholar]
  88. Shafto MA, Tyler LK, Dixon M, Taylor JR, Rowe JB, Cusack R, Calder AJ, Marslen-Wilson WD, Duncan J, Dalgleish T, Henson RN, Brayne C, Matthews FE, Cam-CAN The Cambridge centre for ageing and neuroscience (cam-CAN) study protocol: A cross-sectional, lifespan, multidisciplinary examination of healthy cognitive ageing. BMC Neurology. 2014;14:204. doi: 10.1186/s12883-014-0204-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  89. Shai I, Rosner BA, Shahar DR, Vardi H, Azrad AB, Kanfi A, Schwarzfuchs D, Fraser D, DEARR study Dietary evaluation and attenuation of relative risk: Multiple comparisons between blood and urinary biomarkers, food frequency, and 24-hour recall questionnaires: The DEARR Study. The Journal of Nutrition. 2005;135:573–579. doi: 10.1093/jn/135.3.573. [DOI] [PubMed] [Google Scholar]
  90. Shimizu I, Yoshida Y, Suda M, Minamino T. DNA damage response and metabolic disease. Cell Metabolism. 2014;20:967–977. doi: 10.1016/j.cmet.2014.10.008. [DOI] [PubMed] [Google Scholar]
  91. Simmons JP, Nelson LD, Simonsohn U. A 21 word solution. SSRN Electronic Journal. 2012;14:588. doi: 10.2139/ssrn.2160588. [DOI] [Google Scholar]
  92. Smith PJ, Blumenthal JA, Babyak MA, Craighead L, Welsh-Bohmer KA, Browndyke JN, Strauman TA, Sherwood A. Effects of the dietary approaches to stop hypertension diet, exercise, and caloric restriction on neurocognition in overweight adults with high blood pressure. Hypertension. 2010;55:1331–1338. doi: 10.1161/HYPERTENSIONAHA.109.146795. [DOI] [PMC free article] [PubMed] [Google Scholar]
  93. Smith SM, Vidaurre D, Alfaro-Almagro F, Nichols TE, Miller KL. Estimation of brain age delta from brain imaging. NeuroImage. 2019;200:528–539. doi: 10.1016/j.neuroimage.2019.06.017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  94. Smola AJ, Bartlett P, Schölkopf B, Schuurmans D. Advances in Large-Margin Classifiers. Mitpress; 2000. [DOI] [Google Scholar]
  95. Staubo SC, Aakre JA, Vemuri P, Syrjanen JA, Mielke MM, Geda YE, Kremers WK, Machulda MM, Knopman DS, Petersen RC, Jack CR, Roberts RO. Mediterranean diet, micronutrients and macronutrients, and MRI measures of cortical thickness. Alzheimer’s & Dementia. 2017;13:168–177. doi: 10.1016/j.jalz.2016.06.2359. [DOI] [PMC free article] [PubMed] [Google Scholar]
  96. Tam BT, Morais JA, Santosa S. Obesity and ageing: two sides of the same coin. Obesity Reviews. 2020;21:e12991. doi: 10.1111/obr.12991. [DOI] [PubMed] [Google Scholar]
  97. Taylor JR, Williams N, Cusack R, Auer T, Shafto MA, Dixon M, Tyler LK, Henson RN. The cambridge centre for ageing and neuroscience (cam-CAN) data repository: Structural and functional MRI, MEG, and cognitive data from a cross-sectional adult lifespan sample. NeuroImage. 2017;144:262–269. doi: 10.1016/j.neuroimage.2015.09.018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  98. Thomas EL, Fitzpatrick JA, Malik SJ, Taylor-Robinson SD, Bell JD. Whole body fat: content and distribution. Progress in Nuclear Magnetic Resonance Spectroscopy. 2013;73:56–80. doi: 10.1016/j.pnmrs.2013.04.001. [DOI] [PubMed] [Google Scholar]
  99. Tsaban G, Yaskolka Meir A, Rinott E, Zelicha H, Kaplan A, Shalev A, Katz A, Rudich A, Tirosh A, Shelef I, Youngster I, Lebovitz S, Israeli N, Shabat M, Brikner D, Pupkin E, Stumvoll M, Thiery J, Ceglarek U, Heiker JT, Körner A, Landgraf K, von Bergen M, Blüher M, Stampfer MJ, Shai I. The effect of green Mediterranean diet on cardiometabolic risk; A randomised controlled trial. Heart. 2021;107:1054–1061. doi: 10.1136/heartjnl-2020-317802. [DOI] [PubMed] [Google Scholar]
  100. U.S. Department of Health and Human Services Managing overweight and obesity in adults: Systematic evidence review from the obesity expert panel. 2013. [May 10, 2022]. https://www.nhlbi.nih.gov/health-topics/managing-overweight-obesity-in-adults
  101. Valls-Pedret C, Sala-Vila A, Serra-Mir M, Corella D, de la Torre R, Martínez-González MÁ, Martínez-Lapiscina EH, Fitó M, Pérez-Heras A, Salas-Salvadó J, Estruch R, Ros E. Mediterranean diet and age-related cognitive decline: A randomized clinical trial. JAMA Internal Medicine. 2015;175:1094–1103. doi: 10.1001/jamainternmed.2015.1668. [DOI] [PubMed] [Google Scholar]
  102. Voss MW, Prakash RS, Erickson KI, Basak C, Chaddock L, Kim JS, Alves H, Heo S, Szabo AN, White SM, Wójcicki TR, Mailey EL, Gothe N, Olson EA, McAuley E, Kramer AF. Plasticity of brain networks in a randomized intervention trial of exercise training in older adults. Frontiers in Aging Neuroscience. 2010;2:32. doi: 10.3389/fnagi.2010.00032. [DOI] [PMC free article] [PubMed] [Google Scholar]
  103. Yang Y, Shields GS, Guo C, Liu Y. Executive function performance in obesity and overweight individuals: A meta-analysis and review. Neuroscience and Biobehavioral Reviews. 2018;84:225–244. doi: 10.1016/j.neubiorev.2017.11.020. [DOI] [PubMed] [Google Scholar]
  104. Yaskolka Meir A, Tsaban G, Zelicha H, Rinott E, Kaplan A, Youngster I, Rudich A, Shelef I, Tirosh A, Brikner D, Pupkin E, Sarusi B, Blüher M, Stümvoll M, Thiery J, Ceglarek U, Stampfer MJ, Shai I. A green-mediterranean diet, supplemented with mankai duckweed, preserves iron-homeostasis in humans and Is efficient in reversal of anemia in rats. The Journal of Nutrition. 2019;149:1004–1011. doi: 10.1093/jn/nxy321. [DOI] [PubMed] [Google Scholar]
  105. Yaskolka Meir A, Keller M, Bernhart SH, Rinott E, Tsaban G, Zelicha H, Kaplan A, Schwarzfuchs D, Shelef I, Gepner Y, Li J, Lin Y, Blüher M, Ceglarek U, Stumvoll M, Stadler PF, Stampfer MJ, Kovacs P, Liang L, Shai I. Lifestyle weight-loss intervention may attenuate methylation aging: the CENTRAL MRI randomized controlled trial. Clinical Epigenetics. 2021a;13:48. doi: 10.1186/s13148-021-01038-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  106. Yaskolka Meir A, Rinott E, Tsaban G, Zelicha H, Kaplan A, Rosen P, Shelef I, Youngster I, Shalev A, Blüher M, Ceglarek U, Stumvoll M, Tuohy K, Diotallevi C, Vrhovsek U, Hu F, Stampfer M, Shai I. Effect of green-mediterranean diet on intrahepatic fat: The direct plus randomised controlled trial. Gut. 2021b;70:2085–2095. doi: 10.1136/gutjnl-2020-323106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  107. Yu J, Mathi Kanchi M, Rawtaer I, Feng L, Kumar AP, Kua E-H, Mahendran R. Differences between multimodal brain-age and chronological-age are linked to telomere shortening. Neurobiology of Aging. 2022;115:60–69. doi: 10.1016/j.neurobiolaging.2022.03.015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  108. Zeighami Y, Dadar M, Daoust J, Pelletier M, Biertho L, Bouvet-Bouchard L, Fulton S, Tchernof A, Dagher A, Richard D, Evans A, Michaud A. Impact of weight loss on brain age: improved brain health following bariatric surgery. NeuroImage. 2022;259:119415. doi: 10.1016/j.neuroimage.2022.119415. [DOI] [PubMed] [Google Scholar]
  109. Zelicha H, Kaplan A, Yaskolka Meir A, Tsaban G, Rinott E, Shelef I, Tirosh A, Brikner D, Pupkin E, Qi L, Thiery J, Stumvoll M, Kloting N, von Bergen M, Ceglarek U, Blüher M, Stampfer MJ, Shai I. The effect of wolffia globosa mankai, a green aquatic plant, on postprandial glycemic response: a randomized crossover controlled trial. Diabetes Care. 2019;42:1162–1169. doi: 10.2337/dc18-2319. [DOI] [PubMed] [Google Scholar]
  110. Zelicha H, Kloting N, Kaplan A, Yaskolka Meir A, Rinott E, Tsaban G, Chassidim Y, Bluher M, Ceglarek U, Isermann B, Stumvoll M, Quayson RN, von Bergen M, Engelmann B, Rolle-Kampczyk UE, Haange SB, Tuohy KM, Diotallevi C, Shelef I, Hu FB, Stampfer MJ, Shai I. The effect of high-polyphenol mediterranean diet on visceral adiposity: the direct plus randomized controlled trial. BMC Medicine. 2022;20:327. doi: 10.1186/s12916-022-02525-8. [DOI] [PMC free article] [PubMed] [Google Scholar]

Editor's evaluation

Muthuswamy Balasubramanyam 1

This study is indeed a landmark work that reports the significant benefits of lifestyle intervention in terms of attenuation of brain age and improvement in several tissue-based biomarkers. The findings from this study are of compelling and convincing nature that would encourage and support structured lifestyle intervention as an inclusive part of public health.

Decision letter

Editor: Muthuswamy Balasubramanyam1
Reviewed by: Muthuswamy Balasubramanyam2, Ann-Marie de Lange3

Our editorial process produces two outputs: (i) public reviews designed to be posted alongside the preprint for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.

Decision letter after peer review:

Thank you for submitting your article "The effect of 18 months lifestyle intervention on brain age assessed with resting-state functional connectivity" for consideration by eLife. Your article has been reviewed by 3 peer reviewers, including Muthuswamy Balasubramanyam as the Reviewing Editor and Reviewer #1, and the evaluation has been overseen by Christian Büchel as the Senior Editor. The following individual involved in the review of your submission has agreed to reveal their identity: Ann-Marie de Lange (Reviewer #2).

The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.

Essential revisions:Reviewer 1: (Essential Revisions)

Authors should refer to the articles by Gampawar et al. (2020); Yu et al. (Neurobiol Aging 2022) and Franke & Gaser (2019) and extend/substantiate their discussion.

Reviewer 2: (Essential Revisions)

Introduction: Query 1

The authors could consider an introductory paragraph explaining RSFC and why it was used in this study: how does RSFC link to lifestyle and health, and how does it change with aging (e.g., what characteristics are expected)?

Methods: Queries 1 & 2

1. Line 317: The authors could clarify their inclusion and exclusion criteria. For inclusion criteria, the authors could cite relevant papers defining the cut-off values as thresholds to obesity. For exclusion, are the cut-off values linked to e.g., worse body or brain outcomes, or why were they included? Relevant citations may also be beneficial here.

2. The authors could consider including key details on the intervention study (those listed in SI Table 3), which are integral to the interpretations, in the main body of the text, rather than supplementary analyses (e.g., kcal restrictions). It would also be helpful if the authors could clarify how the randomization to different intervention groups is accounted for in the current study.Reviewer 3: (Essential Revisions)

Answers to comments: 1, 3 & 4

1) The authors did not choose to calculate brain age gap estimates for T0 and T18, but instead projected the brain-predicted age from T0 to T18 and calculated the difference between this 'expected brain age' and the 'observed brain age'. This procedure appears to be rather unusual. Is there any citeable resource that inspired the authors to follow this approach?

2. Question related to: how the effect size of 0.79 was derived.

3. The study uses a variety of variables and it remains uncertain if all relevant variables have been mentioned. For instance, the different categories derived from the food frequency questionnaires have not been described sufficiently. How many categories have been tested for an association with changes in brain age? In order to increase transparency, I suggest providing the "21-word solution" by Simmons et al. (http://dx.doi.org/10.2139/ssrn.2160588): "We report how we determined our sample size, all data exclusions (if any), all manipulations, and all measures in the study." If necessary, this statement might be adjusted to ensure that it is accurate.

Reviewer #1 (Recommendations for the authors):

Authors should consider addressing the comments with additional experiments and revising the manuscript.

Comments:

1) Authors should refer to Yu et al. (Neurobiol Aging 2022) and extend their discussion.

2) Authors should refer to the article by Franke & Gaser (2019) and extend/substantiate their discussion.

Reviewer #2 (Recommendations for the authors):

Introduction

1. The authors could consider an introductory paragraph explaining RSFC and why it was used in this study: how does RSFC link to lifestyle and health, and how does it change with ageing (e.g., what characteristics are expected)?

Results

1. Line 149: For a very restrictive intervention of only 1400 daily kcal for women and 1600 daily kcal for men over a period of 18 months, an average weight loss of 2.3kg seems small, especially in obese subjects. Could this potentially stem from a failure to comply with the intervention, resulting in lower weight loss or weight fluctuations? It would be helpful if the authors could comment on this in their discussion.

Methods

1. Line 317: The authors could clarify their inclusion and exclusion criteria. For inclusion criteria, the authors could cite relevant papers defining the cut-off values as thresholds to obesity. For exclusion, are the cut-off values linked to e.g., worse body or brain outcomes, or why were they included? Relevant citations may also be beneficial here.

2. The authors could consider including key details on the intervention study (those listed in SI Table 3), which are integral to the interpretations, in the main body of the text, rather than supplementary analyses (e.g., kcal restrictions). It would also be helpful if the authors could clarify how the randomisation to different intervention groups is accounted for in the current study.

Reviewer #3 (Recommendations for the authors):

1) The authors did not choose to calculate brain age gap estimates for T0 and T18, but instead projected the brain-predicted age from T0 to T18 and calculated the difference between this 'expected brain age' and the 'observed brain age'. This procedure appears to be rather unusual. Is there any citeable resource that inspired the authors to follow this approach?

2) Brain age was associated with several measures at baseline (Table 2), including chronological age. Usually, researchers in this field report on associations of the brain age gap, bias-corrected for chronological age. In other words, they report on the incremental associations of brain age with other variables, beyond the effects of chronological age. Without correcting for chronological age, associations of brain age with other variables are strongly driven by age. On this account, I feel that the results provided in Table 2 are not very informative with respect to the validity of the brain age estimates. The motivation for showing these statistics (message to the reader), as well as the choice of showing tertiles remains unclear to me.

3) I appreciate that the authors report a power analysis, but with the given information, it is not very comprehensible how the effect size of 0.79 was derived. I assume that this effect size estimate refers to Cohen's d!? Was it calculated based on the t-values and degrees of freedom from the '24-month post-surgery visits compared to baseline' reported in the cited resource? In general, effect sizes observed in single studies do not constitute very reliable estimates. In my view, a better option would be a sensitivity power analysis, which tests the probability (1-β) of different hypothetical effect sizes (e.g., d ranging from 0 to 1.5) to reach significance (α = 0.05) in a sample of respective size (N = 102; Lakens 2022, https://doi.org/10.1525/collabra.33267, see Figure 9).

4) The study uses a variety of variables and it remains uncertain if all relevant variables have been mentioned. For instance, the different categories derived from the food frequency questionnaires have not been described sufficiently. How many categories have been tested for an association with changes in brain age? In order to increase transparency, I suggest providing the "21-word solution" by Simmons et al. (http://dx.doi.org/10.2139/ssrn.2160588): "We report how we determined our sample size, all data exclusions (if any), all manipulations, and all measures in the study." If necessary, this statement might be adjusted to ensure that it is accurate.

eLife. 2023 Apr 6;12:e83604. doi: 10.7554/eLife.83604.sa2

Author response


Essential revisions:

Reviewer #1 (Recommendations for the authors):

Authors should consider addressing the comments with additional experiments and revising the manuscript.

Comments:

1) Authors should refer to Yu et al. (Neurobiol Aging 2022) and extend their discussion.

2) Authors should refer to the article by Franke & Gaser (2019) and extend/substantiate their discussion.

We now relate to both studies in the Discussion section. We refer to our response to the previous comment for the citation from the text.

Reviewer #2 (Recommendations for the authors):

Introduction

1. The authors could consider an introductory paragraph explaining RSFC and why it was used in this study: how does RSFC link to lifestyle and health, and how does it change with ageing (e.g., what characteristics are expected)?

We now include such a paragraph in the Introduction section:

“We previously found that weight loss, glycemic control, and lowering of blood pressure, as well as an increment in polyphenols-rich food, were associated with an attenuation in brain atrophy 12. Obesity is also manifested in age-related changes in the brain’s functional organization as assessed with resting-state functional connectivity (RSFC). These changes are dynamic13 and can be observed in short time scales14 and thus of relevance when studying lifestyle intervention. Studies have linked obesity with decreased connectivity within the default mode network15,16 and increased connectivity with the lateral orbitofrontal cortex17, which are also seen in normal aging18,19. Longitudinal trials have reported changes in these connectivity patterns following weight reduction20,21, indicating that they can be altered. However, findings regarding functional changes are less consistent than those related to anatomical changes due to the multiple measures22 and scales23 used to quantify RSFC. Hence, focusing on a single measure, the functional brain age, may better capture these complex changes and their relation to aging. "

Results

1. Line 149: For a very restrictive intervention of only 1400 daily kcal for women and 1600 daily kcal for men over a period of 18 months, an average weight loss of 2.3kg seems small, especially in obese subjects. Could this potentially stem from a failure to comply with the intervention, resulting in lower weight loss or weight fluctuations? It would be helpful if the authors could comment on this in their discussion.

We thank the reviewer for this important question. As demonstrated by our previous trials as well as by other studies, the maximum weight loss following lifestyle intervention is achieved in six months, where a nadir in weight loss is observed following a regain/rebound phase 24–28. In addition, our trials as well as others have demonstrated an improvement in cardiometabolic health following a Mediterranean diet intervention, i.e., hepatic and visceral fat reduction and improved lipid profile even when only modest weight loss is achieved 26,29,30. Thus, this moderate weight loss does not reflect a failure to comply with the intervention. Instead, it reflects the natural course of weight dynamics following a dietary intervention. Following the reviewer's suggestion, we now include the following text in the Discussion section:

“During the 18-month trial, a modest average weight loss of 2.31 (±5.61) kg was observed. As demonstrated by our previous trials, as well as others, the maximum weight loss following lifestyle intervention is achieved in six months, following a regain/rebound phase. In addition, our trials and others have demonstrated an improvement in cardiometabolic health following a Mediterranean diet intervention (i.e., hepatic and visceral fat reduction and improved lipid profile), despite a modest weight loss42,51–53.”

Methods

1. Line 317: The authors could clarify their inclusion and exclusion criteria. For inclusion criteria, the authors could cite relevant papers defining the cut-off values as thresholds to obesity. For exclusion, are the cut-off values linked to e.g., worse body or brain outcomes, or why were they included? Relevant citations may also be beneficial here.

We thank the reviewer for this question. For the inclusion criteria, the cut-off values of waist circumference (WC): men>102 cm, women>88 cm were adopted from the NIH (https://www.nhlbi.nih.gov/sites/default/files/media/docs/obesity-evidence-review.pdf), and the CDC (cdc.gov/healthyweight/assessing/index.html), and are widely accepted in the literature. (i.e. 31). The cut-off values for triglycerides and HDL were adopted from the American Heart Association guidelines for metabolic syndrome 32. For exclusion criteria, we intended to recruit participants with obesity or dyslipidemia who were otherwise healthy. Thus, participants who were chronically ill (a significant illness that might require hospitalization; active cancer or chemotherapy treatment in the last three years; serum creatinine ≥2 mg/dL) or participants who could not undergo lifestyle or dietary intervention or an MRI scan were also excluded (inability to perform the physical activity; pregnancy or lactation; warfarin treatment due to possible interaction with Wolffia globose which has a high vitamin K content; pacemaker or platinum implantation). Participants with clinically elevated liver enzymes (more than three times the normal range's upper limit) were excluded since our primary endpoint included liver fat and steatohepatitis as a primary outcome.

We now include the relevant citation in the main text as suggested:

“Among 378 volunteers, 294 met age (30+ years of age) and abdominal obesity inclusion criteria [waist circumference (WC): men>102 cm, women>88 cm33,34] or dyslipidemia [TG>150 mg/dL and high-density-lipoprotein-cholesterol (HDL-c) ≤40 mg/dL for men, ≤50 mg/dL for women32]. Exclusion criteria were inability to perform physical activity; serum creatinine ≥2 mg/dL; serum alanine aminotransferase or aspartate aminotransferase more than three times above the upper limit of normal; a major illness that might require hospitalization; pregnancy or lactation; active cancer, or chemotherapy treatment in the last three years; warfarin treatment; pacemaker or platinum implantation; and participation in a different trial.”

2. The authors could consider including key details on the intervention study (those listed in SI Table 3), which are integral to the interpretations, in the main body of the text, rather than supplementary analyses (e.g., kcal restrictions). It would also be helpful if the authors could clarify how the randomisation to different intervention groups is accounted for in the current study.

We now include a summary of the key details of the intervention in Methods section 2.3:

“…all participants received free gym membership, including educational sessions encouraging moderate-intensity PA. Participants in both MED groups were assigned to a diet rich in vegetables, with poultry and fish replacing beef and lamb, with 1500-1800 kcal/day for men, 1200-1400 kcal/day for women. The diet additionally included 28 g/day of walnuts (+440 mg/day polyphenols provided). The green-MED group further consumed green tea (3–4 cups/day) and Wolffia globosa green shake (100 g/ day frozen cubes, +1240 mg/day total polyphenols provided).”

Regarding the randomization procedure, we refer the reviewer to Methods section 2.3:

“All participants completed the baseline measurements and were randomized, using a computer-based program, in a 1:1:1 ratio, stratified by sex and work status (to ensure equal workplace-related lifestyle features between groups), into one of the three intervention groups.”

Reviewer #3 (Recommendations for the authors):

1) The authors did not choose to calculate brain age gap estimates for T0 and T18, but instead projected the brain-predicted age from T0 to T18 and calculated the difference between this 'expected brain age' and the 'observed brain age'. This procedure appears to be rather unusual. Is there any citeable resource that inspired the authors to follow this approach?

We applied the same approach here as in a previous study by our group where we tested methylation aging in the CENTRAL cohort (https://clinicaltrials.gov/ct2/show/NCT01530724):

Yaskolka Meir, A., Keller, M., Bernhart, S. H., Rinott, E., Tsaban, G., Zelicha, H., … & Shai, I. (2021). Lifestyle weight-loss intervention may attenuate methylation aging: the CENTRAL MRI randomized controlled trial. Clinical epigenetics, 13(1), 1-10.

We now cite the relevant publication in sections Results 3.3 and Methods 2.10:

“The primary outcome of the current work was brain age attenuation quantified as the difference between the expected and observed brain age at T18 4

“Brain aging attenuation was quantified as the difference between the expected and observed brain age at T18 4

In response to reviewer #2, comment 2, we demonstrate that this method is identical to subtracting the predicted age at T18 from that of T0 following age bias correction while considering the exact time difference between the two scans.

2) Brain age was associated with several measures at baseline (Table 2), including chronological age. Usually, researchers in this field report on associations of the brain age gap, bias-corrected for chronological age. In other words, they report on the incremental associations of brain age with other variables, beyond the effects of chronological age. Without correcting for chronological age, associations of brain age with other variables are strongly driven by age. On this account, I feel that the results provided in Table 2 are not very informative with respect to the validity of the brain age estimates. The motivation for showing these statistics (message to the reader), as well as the choice of showing tertiles remains unclear to me.

We thank the reviewer for this comment, and we agree that the report of the tertiles was cumbersome. We now omitted it and we report the correlation of age, predicted age, and the bias-corrected brain age gap in Table 1 and SI Table 1 for the entire group.

Within the text we only report the correlation with the bias corrected brain age gap:

“In Table 1 we report the correlation between baseline characteristics and age, predicted age, and the brain-age gap (see SI Table 1 for additional measures). The brain age gap was computed as the difference between the predicted and observed age after regressing out the effect of age on the this gap (brain age bias correction 11). At baseline, brain-age gap was correlated with chemerin (r=0.22, p=0.029), and with obesity-associated measurements obtained by MRI including visceral abdominal tissue (VAT): r=0.23, p=0.02 and superficial subcutaneous fat (SSC): r=-0.25, p=0.014.”

3) I appreciate that the authors report a power analysis, but with the given information, it is not very comprehensible how the effect size of 0.79 was derived. I assume that this effect size estimate refers to Cohen's d!? Was it calculated based on the t-values and degrees of freedom from the '24-month post-surgery visits compared to baseline' reported in the cited resource? In general, effect sizes observed in single studies do not constitute very reliable estimates. In my view, a better option would be a sensitivity power analysis, which tests the probability (1-β) of different hypothetical effect sizes (e.g., d ranging from 0 to 1.5) to reach significance (α = 0.05) in a sample of respective size (N = 102; Lakens 2022, https://doi.org/10.1525/collabra.33267, see Figure 9).

We now include a derivation of our power calculation in SI section 11.3:

“2.11 Effect size in previous work

In a recent study105, the authors reported a significant decrease in δ age 12 months following bariatric surgery. We converted the reported t statistic (t=3.66, p< 0.001, df=85) to an effect size (Cohen's d = 0.79, r = 0.369) using an effect size calculator (https://lbecker.uccs.edu/). Using a sample size calculator (Python statsmodels.stats.power), we found that with an α of 0.05 and β > 0.05, a sample size > 90 is required. With the given sample size (n=102), the probability of failing to reject the null hypothesis under the alternative hypothesis (β, Type II error rate) is 3%. Alternatively, for a Type II error rate lower than 0.1 with the given sample size, an effect size of 0.664 (Cohen's d) is required.”

4) The study uses a variety of variables and it remains uncertain if all relevant variables have been mentioned. For instance, the different categories derived from the food frequency questionnaires have not been described sufficiently. How many categories have been tested for an association with changes in brain age? In order to increase transparency, I suggest providing the "21-word solution" by Simmons et al. (http://dx.doi.org/10.2139/ssrn.2160588): "We report how we determined our sample size, all data exclusions (if any), all manipulations, and all measures in the study." If necessary, this statement might be adjusted to ensure that it is accurate.

We now include the 21 words in the Methods section:

“In line with Simmons et al. (2012) 21-word solution 36, we report how we determined our sample size, all data exclusions, all manipulations, and all measures in the study.”

We now detail how all measures and FFQ variables were selected (Methods 2.6, 2.7):

“All clinical measures tested in the current study were selected a-priori from a large pool of variables taken in the DIRECT-PLUS trial37. These measures were taken from five pre-selected categories: 1. Anthropometry that includes BMI and WC; 2. Liver biomarkers that included AST, ALT, GGT, ALKP, FGF 21, and chemerin; 3. Glycemic markers, including glucose HOMA-IR and HbA1c; 4. Lipids including cholesterol, HDL-C, LDL-C, and triglycerides; 5. Imaging measures included liver fat, VAT, DSC, SSC, and the hippocampal occupancy score.”

“We selected a-priori the questionnaire variables that were associated with brain age attenuation. These variables included the change in the following categories: sweets and beverages, weekly Wolffia globose intake, nut and seeds, eggs and milk, beef, processed food, green tea, and walnuts.”

We now include a Table reporting all correlations of change in all reported food consumption variables to brain age attenuation in Supplementary file 4.

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Data Citations

    1. Taylor JR, Williams N, Cusack R, Auer T, Shafto MA, Dixond M, Dixond LK, Tylerd LK, Cam Can, Richard NH. 2017. Magnetoencephalography (MEG) The Cambridge Centre for Ageing and Neuroscience. [DOI]
    2. Nooner KB, Colcombe SJ, Tobe RH, Mennes M, Benedict MM, Moreno AL, Panek LJ, Brown S, Zavitz ST, Li Q, Sikka S. 2012. NKI-RS Enhanced Sample. International Neuroimaging Data-sharing Initiative. SCR_010461

    Supplementary Materials

    Figure 3—source data 1. Participants’ demographics predicted and observed age and weight values.

    A processed version of the data that includes participants’ demographics, predicted, and observed age and weight values for T0 and T18.

    Supplementary file 1. Intervention outline by group.

    A table describing the details of the intervention for each of the three groups.

    elife-83604-supp1.xlsx (10.2KB, xlsx)
    Supplementary file 2. Association between baseline characteristics and age, predicted age, and brain age gap.

    A table describing the Pearson’s correlation between baseline characteristics and age, predicted age, and brain age gap.

    elife-83604-supp2.xlsx (11KB, xlsx)
    Supplementary file 3. Correlation and partial correlation of brain age attenuation and the measured biomarkers.

    A table describing the Pearson’s correlation and partial correlation of brain age attenuation and the change in the measured biomarkers.

    elife-83604-supp3.xlsx (10.7KB, xlsx)
    Supplementary file 4. Relation between brain age attenuation and food consumption.

    A table describing the Kendall’s tau correlation coefficient of brain age attenuation and food consumption, as reported using a food frequency questionnaire (FFQ).

    elife-83604-supp4.xlsx (9.5KB, xlsx)
    MDAR checklist

    Data Availability Statement

    The code for the brain age prediction model and the calculation of brain age attenuation is openly available online at https://github.com/GidLev/functional_brain_aging (copy archived at Levakov et al., 2023). The unprocessed data used for the model training and validation is openly available online at http://fcon_1000.projects.nitrc.org/indi/enhanced/neurodata.html for the eNKI dataset and available upon online access request https://camcan-archive.mrc-cbu.cam.ac.uk/dataaccess/ for the CamCAN dataset. Data from the DIRECT-PLUS trial is not publicly available since it contains information that could compromise the privacy of research participants. However, de-identified data could be shared upon request, subject to approval from the Soroka Medical Center Medical Ethics Board. A processed version of the data that includes participants' demographics, predicted and observed age and weight values for T0 and T18 is available as Figure 3—source data 1.

    The following previously published datasets were used:

    Taylor JR, Williams N, Cusack R, Auer T, Shafto MA, Dixond M, Dixond LK, Tylerd LK, Cam Can, Richard NH. 2017. Magnetoencephalography (MEG) The Cambridge Centre for Ageing and Neuroscience.

    Nooner KB, Colcombe SJ, Tobe RH, Mennes M, Benedict MM, Moreno AL, Panek LJ, Brown S, Zavitz ST, Li Q, Sikka S. 2012. NKI-RS Enhanced Sample. International Neuroimaging Data-sharing Initiative. SCR_010461


    Articles from eLife are provided here courtesy of eLife Sciences Publications, Ltd

    RESOURCES